Page last updated: 2024-10-16

beta-alanine and Bleeding

beta-alanine has been researched along with Bleeding in 299 studies

Research Excerpts

ExcerptRelevanceReference
"Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation (AF)."10.27Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. ( Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M, 2013)
"The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin."10.27Management and outcomes of major bleeding during treatment with dabigatran or warfarin. ( Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S, 2013)
"Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE."9.19Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. ( Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S, 2014)
"We observed a rate of major bleeding similar to that reported in randomized clinical trials among patients with AF prescribed dabigatran or rivaroxaban."9.19Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. ( Evans, RS; Fontaine, GV; Lloyd, JF; Mathews, KD; Stevens, SM; Woller, SC, 2014)
"Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo."9.17Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. ( Baanstra, D; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Kvamme, AM; Mismetti, P; Schellong, S; Schulman, S, 2013)
"In 18,113 AF patients in the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial, we used a previously developed method for integrating ischemic and bleeding events as "ischemic stroke equivalents" in order to compare a weighted benefit of 2 doses of dabigatran with each other, and with that of warfarin."9.17Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. ( Connolly, SJ; Eikelboom, JW; Hart, RG; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S, 2013)
"3 years of continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily in comparison with 110 mg, and similar rates of stroke and death."9.17The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. ( Alings, M; Amerena, JV; Avezum, A; Baumgartner, I; Brueckmann, M; Budaj, AJ; Chen, JH; Connolly, SJ; Dans, AL; Darius, H; Di Pasquale, G; Duffy, CO; Eikelboom, J; Ezekowitz, MD; Ferreira, J; Flaker, GC; Flather, MD; Franzosi, MG; Golitsyn, SP; Halon, DA; Heidbuchel, H; Hohnloser, SH; Huber, K; Jansky, P; Kamensky, G; Keltai, M; Kim, SS; Lau, CP; Le Heuzey, JY; Lewis, BS; Liu, L; Nanas, J; Oldgren, J; Omar, R; Pais, P; Pedersen, KE; Piegas, LS; Pogue, J; Raev, D; Reilly, PA; Smith, PJ; Talajic, M; Tan, RS; Tanomsup, S; Themeles, E; Toivonen, L; Vinereanu, D; Wallentin, L; Wang, SQ; Xavier, D; Yusuf, S; Zhu, J, 2013)
"The distribution of activated partial thromboplastin time (APTT) in nonvalvular atrial fibrillation (NVAF) patients under dabigatran therapy remains to be clarified."9.16Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time. ( Aizawa, T; Funada, R; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Uejima, T; Yajima, J; Yamashita, T, 2012)
"Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required."9.16Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012)
" The frequencies of stroke and major bleeding within 30 days of cardioversion on the 2 doses of dabigatran were low and comparable to those on warfarin with or without transesophageal echocardiography guidance."9.15Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. ( Aikens, TH; Brugada, J; Chernick, M; Connolly, SJ; Ezekowitz, MD; Flaker, G; Kamensky, G; Nagarakanti, R; Oldgren, J; Parekh, A; Reilly, PA; Yang, S; Yusuf, S, 2011)
"RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an international multicenter study (18,113 patients from 967 centers in 44 countries) that demonstrated the ability of dabigatran to reduce the occurrence of both stroke and hemorrhage in patients who had atrial fibrillation (AF) with high risks of stroke compared with patients who received warfarin."9.15Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. ( Connolly, SJ; Ezekowitz, MD; Hori, M; Reilly, PA; Wallentin, L; Yusuf, S, 2011)
"After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel."9.15Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011)
"In patients with atrial fibrillation at risk for stroke, both doses of dabigatran compared with warfarin have lower risks of both intracranial and extracranial bleeding in patients aged <75 years."9.15Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. ( Alings, M; Connolly, SJ; Diener, HC; Eikelboom, JW; Ezekowitz, M; Franzosi, MG; Healey, JS; Hohnloser, SH; Huber, K; Kaatz, S; Oldgren, J; Reilly, P; Varrone, J; Wallentin, L; Yang, S; Yusuf, S, 2011)
"To evaluate the prognostic importance of CHADS(2) risk score in patients with atrial fibrillation receiving oral anticoagulants, including the vitamin K antagonist warfarin and the direct thrombin inhibitor dabigatran."9.15Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. ( Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2011)
"In October 2011, DTB reviewed the use of dabigatran, the first new oral anticoagulant licensed for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and one or more defined risk factors."8.90{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF. ( , 2014)
"Since the approval of dabigatran etexilate, numerous case reports have suggested the potential dangers of bleeding complications, especially given that there is no known antidote."8.90Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population. ( Brunetti, L; Chen, C; White, J, 2014)
"The primary objective was to assess the cost-effectiveness of new oral anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation."8.89Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. ( Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA, 2013)
"Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation."8.88Preventing cardioembolic stroke in atrial fibrillation with dabigatran. ( Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C, 2012)
"For patients with atrial fibrillation and a high risk of thrombosis, the standard prophylaxis is warfarin, an anticoagulant, at a dose adjusted to the INR."8.88Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients. ( , 2012)
"New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation."8.88An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. ( Ansell, J; Mantha, S, 2012)
"In patients with NVAF at risk of stroke, the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial demonstrated that, compared with warfarin, dabigatran 150 mg b."8.88New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. ( Barrios, V; Escobar, C, 2012)
"Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF)."8.87Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). ( Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Palareti, G; Pengo, V; Poli, D; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A, 2011)
"The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established."7.81Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. ( Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R, 2015)
"It remains unclear whether dabigatran etexilate mesylate is associated with higher risk of bleeding than warfarin sodium in real-world clinical practice."7.81Risk of bleeding with dabigatran in atrial fibrillation. ( Baik, SH; Hernandez, I; Piñera, A; Zhang, Y, 2015)
"Compared with warfarin, periprocedural anticoagulation with dabigatran resulted in fewer minor hemorrhages and total adverse events after AF ablation."7.81Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. ( Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD, 2015)
"Prevalence plots were used to describe the point prevalence (monthly) of dabigatran and rivaroxaban use among 29977 hemodialysis patients with atrial fibrillation."7.81Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. ( Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB, 2015)
"Bleeding and thromboembolic events during the periprocedural period were evaluated in 363 consecutive patients who underwent CA for AF at Nagoya University Hospital, and received uninterrupted dabigatran (n=173) or uninterrupted warfarin (n=190) for periprocedural anticoagulation."7.81Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation. ( Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N, 2015)
" Less bleeding but more acute coronary events with dabigatran, and still no antidote."7.81Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug. ( , 2015)
"Excessive anticoagulation with warfarin can result in acute kidney injury (AKI) by causing glomerular hemorrhage and renal tubular obstruction by red blood cell (RBC) casts in some patients, especially in those with chronic kidney disease (CKD)."7.80Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. ( Brodsky, SV; Hebert, L; Nadasdy, G; Nadasdy, T; Qamri, Z; Rovin, B; Ryan, M; Satoskar, A; Ware, K; Wu, H, 2014)
"Advantages of dabigatran, a thrombin inhibitor, for stroke prevention in patients with atrial fibrillation are numerous."7.80Impaired renal function and bleeding in elderly treated with dabigatran. ( Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L, 2014)
"By using nationwide Danish prescription and patient registries, we identified 11,315 first-time dabigatran users with atrial fibrillation."7.80Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. ( Gorst-Rasmussen, A; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F, 2014)
"Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported."7.80Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. ( Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014)
"Evaluate dabigatran adverse event reports with a reported bleeding event and/or reported fatal outcome compared with warfarin."7.80Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. ( Bress, A; McConeghy, KW; Nutescu, EA; Qato, DM; Wing, C, 2014)
"Clinical trial data suggest that dabigatran and warfarin have similar rates of major bleeding but higher rates of gastrointestinal bleeding."7.80Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. ( Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS, 2014)
" Indication for dabigatran etexilate was ischemic stroke in 101 patients and acute cerebral hemorrhage (CH) due to warfarin in 5 (4."7.80Dabigatran in secondary stroke prevention: clinical experience with 106 patients. ( Alonso Cánovas, A; Cruz, A; DeFelipe-Mimbrera, A; Guillán, M; Masjuan, J; Matute, C; Sainz de la Maza, S; Vera, R, 2014)
" The purpose of this study was to estimate the change in medical costs related to stroke and major bleeding for each NOAC (apixaban, dabigatran, and rivoraxaban) relative to warfarin in a RW NVAF population."7.80Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. ( Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N, 2014)
" New oral anticoagulants (apixaban, rivaroxaban and dabigatran) are recommended for antithrombotic therapy in patients with non-valvular atrial fibrillation (NVAF) with moderate and high risk of stroke."7.80[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. ( Rudakova, AV; Tatarskiĭ, BA, 2014)
"Bleeding complications post-ablation were similar for warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation."7.80A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. ( Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R, 2014)
"We report a case of a patient receiving dabigatran who developed a life-threatening bleeding complication during cardiac ablation that rapidly resolved after administration of Factor Eight Inhibitor Bypassing Activity (FEIBA)."7.79Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. ( Dager, WE; Gosselin, RC; Roberts, AJ, 2013)
"It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors."7.79[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013)
"Alternative anticoagulants to warfarin (dabigatran, rivaroxaban, and apixaban) are becoming available for the prevention of thromboembolic stroke in atrial fibrillation (AF), but there is a lack of information on their comparative effectiveness."7.79Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. ( Hughes, DA; Pink, J; Pirmohamed, M, 2013)
" We evaluated the influence of the putative etiological variables and the bleeding score, HAS-BLED score, on APTT values: age greater than 70 years, renal function, gender, dose of dabigatran, and the concomitant prescription of a P-glycoprotein inhibitor."7.79Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. ( Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Suzuki, M; Tanaka, Y; Yagishita, A; Yokoyama, Y, 2013)
"The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear."7.79Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)
"To identify risk factors which increase the risk of hemorrhage under NOA, we performed a PubMed search for both dabigatran and rivaroxaban, as well as three search terms for hemorrhagic complications."7.79The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. ( Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W, 2013)
"Patients receiving dabigatran were younger and at a lower risk of stroke and bleeding."7.79Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)
" Six months before presentation, the patient was placed on Dabigatran etexilate (Dabigatran) (110 mg BID) for atrial fibrillation."7.79The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis. ( Beydoun, A; Husari, A; Maakaron, JE; Sheik Ammar, A; Taher, A, 2013)
"In patients undergoing AF ablation, periprocedural dabigatran use significantly increases the risk of bleeding or thromboembolic complications compared with uninterrupted warfarin therapy."7.78Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. ( Burkhardt, JD; Chalhoub, F; Coffey, J; D'Avila, A; Di Biase, L; Lakkireddy, D; Mansour, MC; Mohanty, P; Monir, G; Natale, A; Pimentel, R; Reddy, VY; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Shaik, N; Swarup, V; Vanga, SR, 2012)
"To report clinical challenges in managing dabigatran-induced bleeding."7.78Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. ( Cano, EL; Miyares, MA, 2012)
"In our cohort, bleeding-related complications 48 h and 1 week post-ablation were similar for warfarin and dabigatran."7.78A comparison of bleeding complications post-ablation between warfarin and dabigatran. ( Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K, 2012)
"Cost considered: the drugs for the prevention of VTE (apixaban, dabigatran, enoxaparin, fondaparinux, other heparins, rivaroxaban and warfarin) and the complications of VTE in the short term and in 5 years (deep vein thrombosis, pulmonary embolism, bleedings and the post-thrombotic syndrome)."7.78[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012)
"To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF."7.77Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011)
"Dabigatran 150 mg (twice daily) was cost-effective in AF populations at high risk of hemorrhage or high risk of stroke unless international normalized ratio control with warfarin was excellent."7.77Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. ( Gage, BF; Shah, SV, 2011)
"Clinical results of the European Action on Anticoagulation (EAA) computer-assisted dosage study and the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial have been compared."6.79Warfarin or dabigatran for treatment of atrial fibrillation. ( Ibrahim, S; Jespersen, J; Poller, L, 2014)
" Rywaroxaban more frequently causes minor bleeding, whereas treatment with dabigatran is associated with more frequent gastrointestinal adverse symptoms."6.79[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. ( Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L, 2014)
"Dabigatran is a univalent low-molecular-weight direct thrombin inhibitor that has been developed as an alternative to vitamin K antagonists (VKAs)."6.50Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. ( Atallah, R; Bloom, BJ; Eisenberg, MJ; Filion, KB, 2014)
"Dabigatran is an oral anticoagulant that inhibits thrombin but not vitamin K."6.49Dabigatran: life-threatening bleeding. ( , 2013)
"Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1."6.47Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011)
" Additional concerns refer to the dosing-regimens and their practical administration: Fondaparinux, rivaroxaban and dabigatran are dosed to achieve maximum effects very close to their limits of tolerance whereas wide dosing spectra for the low molecular weight herparin (LMWH)'s indicate the potential for dose adaptation and increase."6.47Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux. ( Fareed, J; Hull, R; Welzel, D, 2011)
"Dabigatran (Pradaxa) is a competitive direct thrombin inhibitor approved by the US FDA for prevention of embolic stroke in patients with nonvalvular atrial fibrillation."6.47Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. ( Babu, KM; Boyer, EW; Brown, RS; Ganetsky, M; Salhanick, SD, 2011)
"Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation (AF)."6.27Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. ( Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M, 2013)
"The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin."6.27Management and outcomes of major bleeding during treatment with dabigatran or warfarin. ( Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S, 2013)
" The rate of occurrences of adverse effects and bleeding were lower than those seen in the RE-LY trial."5.40A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. ( Hussin, A; Kaur, S; Muhammad, Z; Omar, R; Rusani, BI; Umadevan, D; Yap, LB, 2014)
"Dabigatran is an oral direct thrombin inhibitor indicated for thromboembolism prophylaxis in patients with nonvalvular atrial fibrillation."5.39Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. ( Chen, BC; Dadzie, KA; Hoffman, RS; Nelson, LS; Sheth, NR; Smith, SW; Winchester, JF, 2013)
"Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events."5.38The use of dabigatran immediately after atrial fibrillation ablation. ( Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012)
"Dabigatran is a direct thrombin inhibitor, acting like other members in its class (bivalirudin, argatroban) to impede the clotting process through selective and reversible binding with both free and clot-bound thrombin."5.38Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. ( Boniface, K; Moore, CH; Scott, J; Snashall, J, 2012)
"We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of dabigatran in patients who had serious bleeding (group A) or required an urgent procedure (group B)."5.20Idarucizumab for Dabigatran Reversal. ( Bernstein, RA; Dubiel, R; Eikelboom, J; Glund, S; Huisman, MV; Hylek, EM; Kam, CW; Kamphuisen, PW; Kreuzer, J; Levy, JH; Pollack, CV; Reilly, PA; Sellke, FW; Stangier, J; Steiner, T; Verhamme, P; Wang, B; Weitz, JI, 2015)
"Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE."5.19Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. ( Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S, 2014)
"We observed a rate of major bleeding similar to that reported in randomized clinical trials among patients with AF prescribed dabigatran or rivaroxaban."5.19Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. ( Evans, RS; Fontaine, GV; Lloyd, JF; Mathews, KD; Stevens, SM; Woller, SC, 2014)
"Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo."5.17Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. ( Baanstra, D; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Kvamme, AM; Mismetti, P; Schellong, S; Schulman, S, 2013)
"In 18,113 AF patients in the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial, we used a previously developed method for integrating ischemic and bleeding events as "ischemic stroke equivalents" in order to compare a weighted benefit of 2 doses of dabigatran with each other, and with that of warfarin."5.17Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. ( Connolly, SJ; Eikelboom, JW; Hart, RG; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S, 2013)
"3 years of continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily in comparison with 110 mg, and similar rates of stroke and death."5.17The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. ( Alings, M; Amerena, JV; Avezum, A; Baumgartner, I; Brueckmann, M; Budaj, AJ; Chen, JH; Connolly, SJ; Dans, AL; Darius, H; Di Pasquale, G; Duffy, CO; Eikelboom, J; Ezekowitz, MD; Ferreira, J; Flaker, GC; Flather, MD; Franzosi, MG; Golitsyn, SP; Halon, DA; Heidbuchel, H; Hohnloser, SH; Huber, K; Jansky, P; Kamensky, G; Keltai, M; Kim, SS; Lau, CP; Le Heuzey, JY; Lewis, BS; Liu, L; Nanas, J; Oldgren, J; Omar, R; Pais, P; Pedersen, KE; Piegas, LS; Pogue, J; Raev, D; Reilly, PA; Smith, PJ; Talajic, M; Tan, RS; Tanomsup, S; Themeles, E; Toivonen, L; Vinereanu, D; Wallentin, L; Wang, SQ; Xavier, D; Yusuf, S; Zhu, J, 2013)
"The trial was terminated prematurely after the enrollment of 252 patients because of an excess of thromboembolic and bleeding events among patients in the dabigatran group."5.17Dabigatran versus warfarin in patients with mechanical heart valves. ( Blatchford, J; Brueckmann, M; Connolly, SJ; Devenny, K; Eikelboom, JW; Friedman, J; Granger, CB; Guiver, K; Harper, R; Kappetein, AP; Khder, Y; Lobmeyer, MT; Maas, H; Mack, MJ; Simoons, ML; Van de Werf, F; Voigt, JU, 2013)
"The distribution of activated partial thromboplastin time (APTT) in nonvalvular atrial fibrillation (NVAF) patients under dabigatran therapy remains to be clarified."5.16Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time. ( Aizawa, T; Funada, R; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Uejima, T; Yajima, J; Yamashita, T, 2012)
"Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required."5.16Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012)
" The frequencies of stroke and major bleeding within 30 days of cardioversion on the 2 doses of dabigatran were low and comparable to those on warfarin with or without transesophageal echocardiography guidance."5.15Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. ( Aikens, TH; Brugada, J; Chernick, M; Connolly, SJ; Ezekowitz, MD; Flaker, G; Kamensky, G; Nagarakanti, R; Oldgren, J; Parekh, A; Reilly, PA; Yang, S; Yusuf, S, 2011)
"RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an international multicenter study (18,113 patients from 967 centers in 44 countries) that demonstrated the ability of dabigatran to reduce the occurrence of both stroke and hemorrhage in patients who had atrial fibrillation (AF) with high risks of stroke compared with patients who received warfarin."5.15Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. ( Connolly, SJ; Ezekowitz, MD; Hori, M; Reilly, PA; Wallentin, L; Yusuf, S, 2011)
"After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel."5.15Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011)
"In patients with atrial fibrillation at risk for stroke, both doses of dabigatran compared with warfarin have lower risks of both intracranial and extracranial bleeding in patients aged <75 years."5.15Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. ( Alings, M; Connolly, SJ; Diener, HC; Eikelboom, JW; Ezekowitz, M; Franzosi, MG; Healey, JS; Hohnloser, SH; Huber, K; Kaatz, S; Oldgren, J; Reilly, P; Varrone, J; Wallentin, L; Yang, S; Yusuf, S, 2011)
"To evaluate the prognostic importance of CHADS(2) risk score in patients with atrial fibrillation receiving oral anticoagulants, including the vitamin K antagonist warfarin and the direct thrombin inhibitor dabigatran."5.15Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. ( Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2011)
"In patients undergoing hip or knee arthroplasty, enoxaparin and dabigatran showed similar rates of efficacy and bleeding."5.14Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. ( Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S, 2010)
"In October 2011, DTB reviewed the use of dabigatran, the first new oral anticoagulant licensed for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and one or more defined risk factors."4.90{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF. ( , 2014)
" In Thrombin Receptor Antagonists for Clinical Event Reduction (TRA-CER), compared with standard care alone, bleeding complications including intracranial hemorrhage (ICH) were increased with the addition of vorapaxar, without efficacy benefit."4.90New antithrombotics for secondary prevention of acute coronary syndrome. ( Goto, S; Tomita, A, 2014)
"During the past four years the phase III trials on stroke prophylaxis in atrial fibrillation and on treatment of venous thromboembolism have been completed for four new oral anticoagulants - dabigatran, apixaban, edoxaban and rivaroxaban."4.90New oral anticoagulant agents - general features and outcomes in subsets of patients. ( Schulman, S, 2014)
"Since the approval of dabigatran etexilate, numerous case reports have suggested the potential dangers of bleeding complications, especially given that there is no known antidote."4.90Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population. ( Brunetti, L; Chen, C; White, J, 2014)
" In the second part of the review is discussed higher incidence of myocardial infarction in controlled group in the trial comparing treatment of dabigatran with warfarin."4.90[Anticoagulant therapy in secondary prevention of coronary events]. ( Bultas, J, 2014)
" If bleeding occurs in patients who have received these agents, common principles of bleeding management as with any anticoagulant (including the known principles for warfarin) should be considered."4.89Managing new oral anticoagulants in the perioperative and intensive care unit setting. ( Douketis, JD; Faraoni, D; Levy, JH; Samama, CM; Spring, JL, 2013)
" This review discusses current anticoagulation reversal recommendations for the oral anticoagulants warfarin, dabigatran, and rivaroxaban for patients at a heightened risk of bleeding, actively bleeding, or those in need of preprocedural anticoagulation reversal."4.89Reversal of oral anticoagulation. ( Limdi, NA; Thigpen, JL, 2013)
"Dabigatran was the first of a new generation of anticoagulation drugs for the indication of non-valvular atrial fibrillation (AF) to be approved."4.89Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide. ( Asmussen, MB; Hesselbjerg, LJ; Pedersen, HS; Petersen, KD, 2013)
"Dabigatran is an oral, direct, and competitive inhibitor of thrombin, which is administered to patients with non-valvular atrial fibrillation for prevention of stroke at a dose of 110 mg twice daily or 150 mg twice daily."4.89[Direct oral thrombin inhibitor, "dabigatran"]. ( Yasaka, M, 2013)
"This article will provide a brief introduction to these new oral anticoagulants and then review the approaches that can be taken for the emergency management of hemostasis in patients bleeding or at risk for bleeding while receiving warfarin or one of two newer agents, the direct thrombin inhibitor dabigatran or the factor Xa inhibitor rivaroxaban."4.89Managing bleeding in anticoagulated patients in the emergency care setting. ( Pollack, CV, 2013)
"The primary objective was to assess the cost-effectiveness of new oral anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation."4.89Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. ( Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA, 2013)
"To summarise and compare the efficacy and safety of various oral anticoagulants (dabigatran, rivaroxaban, apixaban, and vitamin K antagonists) and antiplatelet agents (acetylsalicylic acid) for the secondary prevention of venous thromboembolism."4.89Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. ( Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS, 2013)
" Dabigatran: elderly patients with renal failure are at higher risk of bleeding."4.89[Pharmacovigilance update]. ( Livio, F, 2013)
"Dabigatran and rivaroxaban are novel anticoagulants that have been approved for the prevention of thromboembolic events in atrial fibrillation."4.89Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians. ( Brem, E; Foran, M; Koyfman, A, 2013)
" Clinicians need to be aware of some of the drawbacks associated with the use of dabigatran and, in particular, its reduced clearance in the setting of renal failure and the lack of an effective reversing agent when bleeding does occur."4.89Thrombin inhibitors: surgical considerations and pharmacology. ( Breik, O; Devitt, P; Tadros, R, 2013)
"Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation."4.88Preventing cardioembolic stroke in atrial fibrillation with dabigatran. ( Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C, 2012)
"Warfarin has long been considered the gold standard for stroke prevention in patients with atrial fibrillation (AF)."4.88ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation? ( Parma, Z; Syzdół, M; Tendera, M, 2012)
"The present systematic review was conducted to assess the efficacy and safety of apixaban versus other anticoagulants, for the prevention of venous thromboembolism (VTE) following total hip replacement (THR) and total knee replacement (TKR) surgery."4.88The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. ( Cohen, A; Drost, P; Marchant, N; Mitchell, S; Orme, M; Rublee, D; Simon, TA; Sutton, A, 2012)
"For patients with atrial fibrillation and a high risk of thrombosis, the standard prophylaxis is warfarin, an anticoagulant, at a dose adjusted to the INR."4.88Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients. ( , 2012)
" New platelet inhibitors prasugrel and ticagrelor are more effective than the traditional clopidogrel, but their use is also accompanied by more frequent bleeding complications."4.88[New antithrombotic drugs]. ( Mustonen, P; Puurunen, M, 2012)
"New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation."4.88An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. ( Ansell, J; Mantha, S, 2012)
"In this overview we address the three phase III studies that compared new oral anticoagulants (dabigatran, rivaroxaban and apixaban) with warfarin in the setting of stroke prevention in atrial fibrillation."4.88Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. ( Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A, 2012)
" Dabigatran, does not require dose-adjustment and appears to be more effective at reducing the risk of stroke with similar risks of bleeding in patients with atrial fibrillation (AF)."4.88Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison. ( Alonso-Coello, P; Guyatt, G; Zhou, Q, 2012)
" The factor Xa inhibitor, rivaroxaban, has shown promising results in the treatment of acute coronary syndrome but is not yet approved for that indication."4.88What did we learn from new oral anticoagulant treatment? ( Esmon, CT, 2012)
"We present data on possibility of anticoagulant therapy in conjunction with electrical cardioversion in patients with atrial fibrillation using novel anticoagulant - dabigatran - and a case of successful lysis of thrombus in the left ventricular cavity at the background of its administration."4.88[Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation]. ( Dovgalevskiĭ, IaP; Furman, NV; Kuvshinova, LE, 2012)
"In patients with NVAF at risk of stroke, the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial demonstrated that, compared with warfarin, dabigatran 150 mg b."4.88New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. ( Barrios, V; Escobar, C, 2012)
"Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF)."4.87Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). ( Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Palareti, G; Pengo, V; Poli, D; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A, 2011)
"The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established."3.81Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. ( Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R, 2015)
"It remains unclear whether dabigatran etexilate mesylate is associated with higher risk of bleeding than warfarin sodium in real-world clinical practice."3.81Risk of bleeding with dabigatran in atrial fibrillation. ( Baik, SH; Hernandez, I; Piñera, A; Zhang, Y, 2015)
"Although dabigatran, an oral direct thrombin inhibitor, does not require routine monitoring, high plasma concentration of dabigatran (PDC) at trough level is shown to be a high risk for bleeding in patients with nonvalvular atrial fibrillation (NVAF)."3.81CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough. ( Horiuchi, D; Ishida, Y; Itoh, T; Kimura, M; Kinjo, T; Okumura, K; Owada, S; Sasaki, K; Sasaki, S; Tomita, H, 2015)
"Compared with warfarin, periprocedural anticoagulation with dabigatran resulted in fewer minor hemorrhages and total adverse events after AF ablation."3.81Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. ( Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD, 2015)
"Prevalence plots were used to describe the point prevalence (monthly) of dabigatran and rivaroxaban use among 29977 hemodialysis patients with atrial fibrillation."3.81Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. ( Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB, 2015)
"A report has demonstrated that in patients with atrial fibrillation the novel oral anticoagulant, dabigatran, increases the risk of gastrointestinal bleeding by nearly twofold compared with warfarin."3.81Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants. ( Rockey, DC, 2015)
"Severe bleeding associated with dabigatran frequently requires intensive care management."3.81Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. ( Bernier-Jean, A; Bouchard, J; Eris, JM; Ghannoum, M; Kershaw, G; Patel, JP; Roberts, DM; Tran, H; Weatherburn, C; Williamson, D, 2015)
"The objectives of this national chart audit (January to June 2013) of 6,346 patients with atrial fibrillation (AF; ≥18 years without a significant heart valve disorder) from 647 primary care physicians were to (1) describe the frequency of stroke and bleed risk assessments in patients with nonvalvular AF by primary care physicians, including the accuracy of these assessments relative to established predictive indexes; (2) outline contemporary methods of anticoagulation used; and (3) report the time in the therapeutic range among patients prescribed warfarin."3.81Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit). ( Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH, 2015)
"Bleeding and thromboembolic events during the periprocedural period were evaluated in 363 consecutive patients who underwent CA for AF at Nagoya University Hospital, and received uninterrupted dabigatran (n=173) or uninterrupted warfarin (n=190) for periprocedural anticoagulation."3.81Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation. ( Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N, 2015)
"Twenty-seven patients taking dabigatran underwent 41 cutaneous surgeries, with only 1 mild bleeding complication observed that was remedied with a pressure dressing."3.81Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery. ( Arpey, CJ; Baum, CL; Brewer, JD; Chang, TW; Hochwalt, PC; Hocker, TL; Otley, CC; Roenigk, RK, 2015)
" Less bleeding but more acute coronary events with dabigatran, and still no antidote."3.81Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug. ( , 2015)
"Excessive anticoagulation with warfarin can result in acute kidney injury (AKI) by causing glomerular hemorrhage and renal tubular obstruction by red blood cell (RBC) casts in some patients, especially in those with chronic kidney disease (CKD)."3.80Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. ( Brodsky, SV; Hebert, L; Nadasdy, G; Nadasdy, T; Qamri, Z; Rovin, B; Ryan, M; Satoskar, A; Ware, K; Wu, H, 2014)
"In the RE-LY trial dabigatran 150 mg twice daily (D150) showed significantly fewer strokes, and 110 mg (D110) significantly fewer major bleeding events (MBE) compared to well-controlled warfarin in patients with atrial fibrillation (AF)."3.80Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. ( Clemens, A; Connolly, SJ; Ferreira, J; Lip, GY; Noack, H; Yusuf, S, 2014)
"Dabigatran is a direct thrombin inhibitor indicated for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation."3.80[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery]. ( Bachellerie, B; Conil, JM; Crognier, L; Fourcade, O; Georges, B; Ruiz, S; Seguin, T, 2014)
" Therefore, we compared the incidence of bleeding and thrombo-embolic complications following cardiac rhythm device (CRD) implantations under dabigatran vs."3.80Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations. ( Bollmann, A; Breithardt, OA; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P, 2014)
"Advantages of dabigatran, a thrombin inhibitor, for stroke prevention in patients with atrial fibrillation are numerous."3.80Impaired renal function and bleeding in elderly treated with dabigatran. ( Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L, 2014)
"By using nationwide Danish prescription and patient registries, we identified 11,315 first-time dabigatran users with atrial fibrillation."3.80Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. ( Gorst-Rasmussen, A; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F, 2014)
" We determined intracerebral hemorrhage volume and functional outcome in a standardized TBI model in mice treated with warfarin or dabigatran."3.80Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation. ( Foerch, C; Lauer, A; Leung, W; Lo, EH; Lok, J; Schaefer, JH; Van Cott, EM; van Leyen, K; van Ryn, J; Whalen, M; Wu, L, 2014)
"Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported."3.80Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. ( Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014)
"Evaluate dabigatran adverse event reports with a reported bleeding event and/or reported fatal outcome compared with warfarin."3.80Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. ( Bress, A; McConeghy, KW; Nutescu, EA; Qato, DM; Wing, C, 2014)
"New oral anticoagulants (NOACs) offer an alternative to warfarin for preventing stroke in patients with atrial fibrillation."3.80Perioperative management of patients on new oral anticoagulants. ( Davidson, N; Galloway, SW; Lai, A; Thachil, J, 2014)
" Adherence to dabigatran was not associated with non-fatal bleeding or myocardial infarction."3.80Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. ( Barón, AE; Bradley, SM; Carey, EP; Cunningham, F; Grunwald, GK; Ho, PM; Jackevicius, CA; Maddox, TM; Marzec, LN; Pilote, L; Rumsfeld, JS; Schneider, PM; Shore, S; Turakhia, MP; Varosy, PD, 2014)
"This study evaluated differences in medical costs associated with clinical end-points from randomized clinical trials that compared the new oral anticoagulants (NOACs), dabigatran, rivaroxaban, apixaban, and edoxaban, to standard therapy for treatment of patients with venous thromboembolism (VTE)."3.80Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients. ( Amin, A; Graham, J; Jing, Y; Lin, J; Lingohr-Smith, M; Trocio, J, 2014)
"Dabigatran, an oral direct thrombin inhibitor, possesses several advantages over warfarin that can in principle simplify the management of stroke prevention in atrial fibrillation (AF)."3.80Continuation of dabigatran therapy in "real-world" practice in Hong Kong. ( Chan, EW; Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Leung, GK; Siu, CW; Tse, HF, 2014)
"Clinical trial data suggest that dabigatran and warfarin have similar rates of major bleeding but higher rates of gastrointestinal bleeding."3.80Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. ( Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS, 2014)
" Indication for dabigatran etexilate was ischemic stroke in 101 patients and acute cerebral hemorrhage (CH) due to warfarin in 5 (4."3.80Dabigatran in secondary stroke prevention: clinical experience with 106 patients. ( Alonso Cánovas, A; Cruz, A; DeFelipe-Mimbrera, A; Guillán, M; Masjuan, J; Matute, C; Sainz de la Maza, S; Vera, R, 2014)
" The purpose of this study was to estimate the change in medical costs related to stroke and major bleeding for each NOAC (apixaban, dabigatran, and rivoraxaban) relative to warfarin in a RW NVAF population."3.80Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. ( Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N, 2014)
"Dabigatran, a direct thrombin inhibitor, is licensed for the prevention of venous thromboembolism after knee and hip replacement, the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of acute venous thromboembolism."3.80Dabigatran: patient management in specific clinical settings. ( Binder, K; Domanovits, H; Eichinger, S; Függer, R; Gollackner, B; Hiesmayr, JM; Huber, K; Kyrle, PA; Lang, W; Perger, P; Quehenberger, P; Roithinger, FX; Schmaldienst, S; Weltermann, A, 2014)
" New oral anticoagulants (apixaban, rivaroxaban and dabigatran) are recommended for antithrombotic therapy in patients with non-valvular atrial fibrillation (NVAF) with moderate and high risk of stroke."3.80[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. ( Rudakova, AV; Tatarskiĭ, BA, 2014)
" Dabigatran has emerged as a promising alternative to vitamin K antagonists (VKAs) in non-valvular atrial fibrillation (NVAF)."3.80[Eligibility for dabigatran therapy: the real-life experience of a Tuscany general hospital]. ( Banfi, R; Fallani, F; Palazzi, N; Pugi, A, 2014)
"Bleeding complications post-ablation were similar for warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation."3.80A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. ( Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R, 2014)
" A direct thrombin inhibitor, dabigatran etexilate (hereinafter referred to as dabigatran) was approved in the Russian Federation for prevention of thromboembolic complications in orthopaedic practice (2009), for prevention of ischaemic embologenic stroke in atrial fibrillation (2011) and for treatment of recurrent thrombosis of deep veins and pulmonary artery thromboembolism (2014)."3.80[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor]. ( Beliavskaia, OO; Vavilova, TV, 2014)
"We report a case of a patient receiving dabigatran who developed a life-threatening bleeding complication during cardiac ablation that rapidly resolved after administration of Factor Eight Inhibitor Bypassing Activity (FEIBA)."3.79Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. ( Dager, WE; Gosselin, RC; Roberts, AJ, 2013)
"This was a prospective observational study of ED patients under treatment with dabigatran or warfarin who were admitted with bleeding complications during a 6-month period."3.79Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. ( Berger, R; Chase, M; Ganetsky, M; Salhanick, SD, 2013)
"It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors."3.79[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013)
"Alternative anticoagulants to warfarin (dabigatran, rivaroxaban, and apixaban) are becoming available for the prevention of thromboembolic stroke in atrial fibrillation (AF), but there is a lack of information on their comparative effectiveness."3.79Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. ( Hughes, DA; Pink, J; Pirmohamed, M, 2013)
"To reverse the anticoagulant effects of warfarin in patients who are bleeding or need surgery, exogenous vitamin K (phytonadione) may be used in combination with another, shorter-acting intervention, such as fresh frozen plasma (FFP), prothrombin complex concentrate (PCC), recombinant factor VIIa, or activated PCC (aPCC)."3.79Pharmacologic interventions for reversing the effects of oral anticoagulants. ( Kalus, JS, 2013)
" We evaluated the influence of the putative etiological variables and the bleeding score, HAS-BLED score, on APTT values: age greater than 70 years, renal function, gender, dose of dabigatran, and the concomitant prescription of a P-glycoprotein inhibitor."3.79Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. ( Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Suzuki, M; Tanaka, Y; Yagishita, A; Yokoyama, Y, 2013)
"The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear."3.79Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)
"To determine the risk of bleeding and thromboembolic complications associated with uninterrupted OAC during CIED implantation, replacement, or revision, the outcomes of patients receiving uninterrupted dabigatran (D) were compared to those receiving warfarin (W)."3.79Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin. ( Doppalapudi, H; Gunter, A; Jennings, JM; Kay, GN; McElderry, HT; Osorio, J; Plumb, VJ; Robichaux, R; Yamada, T, 2013)
"To identify risk factors which increase the risk of hemorrhage under NOA, we performed a PubMed search for both dabigatran and rivaroxaban, as well as three search terms for hemorrhagic complications."3.79The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. ( Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W, 2013)
"The anticoagulant dabigatran has no reversal agent and may cause life-threatening bleeding in patients with trauma or closed-space hemorrhage."3.79Intravenous lipid emulsion does not reverse dabigatran-induced anticoagulation in a rat model. ( Blum, J; Carreiro, S; Hack, JB, 2013)
"Patients receiving dabigatran were younger and at a lower risk of stroke and bleeding."3.79Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)
" Six months before presentation, the patient was placed on Dabigatran etexilate (Dabigatran) (110 mg BID) for atrial fibrillation."3.79The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis. ( Beydoun, A; Husari, A; Maakaron, JE; Sheik Ammar, A; Taher, A, 2013)
"In patients undergoing AF ablation, periprocedural dabigatran use significantly increases the risk of bleeding or thromboembolic complications compared with uninterrupted warfarin therapy."3.78Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. ( Burkhardt, JD; Chalhoub, F; Coffey, J; D'Avila, A; Di Biase, L; Lakkireddy, D; Mansour, MC; Mohanty, P; Monir, G; Natale, A; Pimentel, R; Reddy, VY; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Shaik, N; Swarup, V; Vanga, SR, 2012)
"For patients with nonrheumatic AF, including those with paroxysmal AF, who are (1) at low risk of stroke (eg, CHADS(2) [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score of 0), we suggest no therapy rather than antithrombotic therapy, and for patients choosing antithrombotic therapy, we suggest aspirin rather than oral anticoagulation or combination therapy with aspirin and clopidogrel; (2) at intermediate risk of stroke (eg, CHADS(2) score of 1), we recommend oral anticoagulation rather than no therapy, and we suggest oral anticoagulation rather than aspirin or combination therapy with aspirin and clopidogrel; and (3) at high risk of stroke (eg, CHADS(2) score of ≥ 2), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel."3.78Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ, 2012)
"To report clinical challenges in managing dabigatran-induced bleeding."3.78Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. ( Cano, EL; Miyares, MA, 2012)
"Dabigatran, an oral thrombin inhibitor, and rivaroxaban and apixaban, oral factor Xa inhibitors, have been found to be safe and effective in reducing stroke risk in patients with atrial fibrillation."3.78Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. ( Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S, 2012)
"We compared efficacy and safety of warfarin, direct thrombin inhibitor dabigatran and clopidogrel in prevention of stroke in 210 patients with nonvalvular atrial fibrillation (AF) aged 65-80 years."3.78[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. ( Kanorskiĭ, SG; Shevelev, VI, 2012)
"In our cohort, bleeding-related complications 48 h and 1 week post-ablation were similar for warfarin and dabigatran."3.78A comparison of bleeding complications post-ablation between warfarin and dabigatran. ( Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K, 2012)
"We present four cases of dabigatran-related bleeding."3.78Hemorrhagic complications associated with dabigatran use. ( Basciano, P; Chen, BC; Garlich, FM; Hoffman, RS; Howland, MA; Nelson, LS; Smith, SW; Viny, AD, 2012)
"We compared the efficacy and safety of warfarin, dabigartan, and clopidogrel used to prevent tromboembolism in 210 elderly patients with non-valvular atrial fibrillation depending on the age."3.78[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation]. ( Kanorsky, SG; Shevelev, VI, 2012)
"Cost considered: the drugs for the prevention of VTE (apixaban, dabigatran, enoxaparin, fondaparinux, other heparins, rivaroxaban and warfarin) and the complications of VTE in the short term and in 5 years (deep vein thrombosis, pulmonary embolism, bleedings and the post-thrombotic syndrome)."3.78[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012)
"To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF."3.77Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011)
"Dabigatran 150 mg (twice daily) was cost-effective in AF populations at high risk of hemorrhage or high risk of stroke unless international normalized ratio control with warfarin was excellent."3.77Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. ( Gage, BF; Shah, SV, 2011)
"Clinical results of the European Action on Anticoagulation (EAA) computer-assisted dosage study and the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial have been compared."2.79Warfarin or dabigatran for treatment of atrial fibrillation. ( Ibrahim, S; Jespersen, J; Poller, L, 2014)
" Rywaroxaban more frequently causes minor bleeding, whereas treatment with dabigatran is associated with more frequent gastrointestinal adverse symptoms."2.79[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. ( Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L, 2014)
"These trials enrolled 5167 people with cancer and VTE."2.58Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. ( Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE, 2018)
"Dabigatran is an oral direct thrombin inhibitor (DTI) licensed for stroke prevention in atrial fibrillation and likely to be soon approved in Europe for treatment of venous thrombosis."2.50The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. ( Alikhan, R; Baglin, T; Benson, G; Green, L; Keeling, D; Marshall, S; Patel, R; Pavord, S; Rayment, R; Rose, P; Tait, C, 2014)
"Dabigatran is a univalent low-molecular-weight direct thrombin inhibitor that has been developed as an alternative to vitamin K antagonists (VKAs)."2.50Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. ( Atallah, R; Bloom, BJ; Eisenberg, MJ; Filion, KB, 2014)
" They are at least as effective and as safe as conventional therapy (heparins and vitamin-K inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring."2.50Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. ( Bounameaux, H; Fontana, P; Goldhaber, SZ, 2014)
"Warfarin and heparins have been the predominant anticoagulants used until the past decade."2.50The newer direct oral anticoagulants: a practical guide. ( Thachil, J, 2014)
"Dabigatran is a direct thrombin (factor IIa) inhibitor; rivaroxaban and apixaban are direct factor Xa inhibitors."2.50Newer clinically available antithrombotics and their antidotes. ( Lévy, S, 2014)
"Ease of dosing and simplicity of monitoring make new oral anticoagulants an attractive therapy in a growing range of clinical conditions."2.50Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates. ( Baumann Kreuziger, LM; Dries, DJ; Keenan, JC; Morton, CT, 2014)
"Dabigatran is an oral anticoagulant that inhibits thrombin but not vitamin K."2.49Dabigatran: life-threatening bleeding. ( , 2013)
" Consequently, if renal function is impaired, there is a risk of drug accumulation that is highest for dabigatran followed by rivaroxaban and then apixaban and thus dosing recommendations are different."2.49Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. ( Böhm, M; Dichgans, M; Diener, HC; Ell, C; Endres, M; Epple, C; Grond, M; Laufs, U; Nickenig, G; Riess, H; Röther, J; Schellinger, PD; Spannagl, M; Steiner, T; Veltkamp, R, 2013)
"Dabigatran is an oral direct thrombin inhibitor widely used to prevent and treat various thromboembolic complications."2.49Dabigatran and kidney disease: a bad combination. ( Berns, JS; Chaknos, CM; Knauf, F; Perazella, MA, 2013)
" If the dosage of the drug is not immediately available, proposals only based on the usual tests, PT and aPTT, also are presented."2.49[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013]. ( Albaladejo, P; Blais, N; Cohen, A; de Maistre, E; Fontana, P; Godier, A; Gruel, Y; Llau, JV; Mismetti, P; Pernod, G; Rosencher, N; Samama, CM; Samama, MM; Schved, JF; Sié, P; Susen, S, 2013)
"Risk for symptomatic deep venous thrombosis, but not risk for death or nonfatal pulmonary embolism, was reduced with factor Xa inhibitors compared with LMWH (4 fewer events per 1000 patients)."2.49Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. ( Adam, SS; Lachiewicz, PF; McDuffie, JR; Ortel, TL; Williams, JW, 2013)
"Dabigatran has been introduced into the prevention of stroke in patients with atrial fibrillation."2.48[Dabigatran and emergency operation on a peritonitis patient]. ( Ilmakunnas, M; Lassila, R; Louhimo, J, 2012)
" The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option."2.48Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. ( Halperin, JL; Varughese, CJ, 2012)
"Cardioembolic cerebral ischemia can be prevented."2.48[Prevention of cardioembolic stroke]. ( Gil Núñez, A, 2012)
" Linearity of dose-response and responsiveness to increasing dose in addition to standardization are other important issues to consider."2.48Laboratory tests and the new oral anticoagulants. ( Tripodi, A, 2012)
" Experience with long-term use (> 5 years) is limited."2.48[Clinical pharmacological aspects of new oral anticoagulants]. ( Haschke, M, 2012)
"Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1."2.47Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011)
" Additional concerns refer to the dosing-regimens and their practical administration: Fondaparinux, rivaroxaban and dabigatran are dosed to achieve maximum effects very close to their limits of tolerance whereas wide dosing spectra for the low molecular weight herparin (LMWH)'s indicate the potential for dose adaptation and increase."2.47Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux. ( Fareed, J; Hull, R; Welzel, D, 2011)
" Clinicians are increasingly being challenged with making uncertain anticoagulant dosing decisions, as the optimal dosing strategy for most anticoagulants in the obese patient population remains unknown."2.47Anticoagulating obese patients in the modern era. ( Arya, R; Patel, JP; Roberts, LN, 2011)
"Dabigatran (Pradaxa) is a competitive direct thrombin inhibitor approved by the US FDA for prevention of embolic stroke in patients with nonvalvular atrial fibrillation."2.47Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. ( Babu, KM; Boyer, EW; Brown, RS; Ganetsky, M; Salhanick, SD, 2011)
"Dabigatran is an oral direct thrombin inhibitor with a rapid onset."2.47Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor. ( Augoustides, JG, 2011)
"Intracorneal hemorrhages are a rare finding generally associated with surgery or trauma."1.72Case Report: Intracorneal Hemorrhages Seen with Scleral Contact Lens Wear and Netarsudil Therapy. ( Crum, AR; Srikumaran, D, 2022)
"Compared to Vitamin K antagonists (VKA), novel oral anticoagulants (NOACs) appear to be safer in terms of major bleeding risks with added advantage of having fixed dosing schedules when used in patients with non-valvular atrial fibrillation (AF)."1.42Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants. ( Aryal, MR; Badal, M; Chaudhary, A; Donato, AA; Mege, J, 2015)
" The rate of occurrences of adverse effects and bleeding were lower than those seen in the RE-LY trial."1.40A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. ( Hussin, A; Kaur, S; Muhammad, Z; Omar, R; Rusani, BI; Umadevan, D; Yap, LB, 2014)
"Dabigatran is a novel oral anticoagulant for which a well-defined range of toxicity and proven antidote has not been established."1.40Evaluation of dabigatran exposures reported to poison control centers. ( Conway, SE; Harrison, DL; Schaeffer, SE, 2014)
"Dabigatran is a new oral direct thrombin inhibitor."1.40Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study. ( Engström, M; Johansson, PI; Nilsson, CU; Ostrowski, SR; Sølbeck, S, 2014)
"Dabigatran is an oral direct thrombin inhibitor indicated for thromboembolism prophylaxis in patients with nonvalvular atrial fibrillation."1.39Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. ( Chen, BC; Dadzie, KA; Hoffman, RS; Nelson, LS; Sheth, NR; Smith, SW; Winchester, JF, 2013)
"Dabigatran is an oral direct thrombin inhibitor that does not require routine laboratory monitoring."1.39The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. ( Butler, J; Chunilal, S; Hapgood, G; Malan, E; Tran, H, 2013)
"Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events."1.38The use of dabigatran immediately after atrial fibrillation ablation. ( Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012)
"Dabigatran is a direct thrombin inhibitor, acting like other members in its class (bivalirudin, argatroban) to impede the clotting process through selective and reversible binding with both free and clot-bound thrombin."1.38Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. ( Boniface, K; Moore, CH; Scott, J; Snashall, J, 2012)
"Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs)."1.38Dabigatran (Pradaxa). ( Comin, J; Kallmes, DF, 2012)
"Valve thrombus was observed in all study groups."1.38Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model. ( Bianco, RW; Lahti, MT; Medina, EM; Schomburg, JL, 2012)
"Neurolathyrism (NL) is a motor neuron disease characterized by spastic paraparesis in the hind legs."1.38Vascular insult accompanied by overexpressed heme oxygenase-1 as a pathophysiological mechanism in experimental neurolathyrism with hind-leg paraparesis. ( Kawaguchi, K; Kusama-Eguchi, K; Lambein, F, 2012)

Research

Studies (299)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's298 (99.67)24.3611
2020's1 (0.33)2.80

Authors

AuthorsStudies
Crum, AR1
Srikumaran, D1
Kahale, LA1
Hakoum, MB1
Tsolakian, IG1
Matar, CF1
Terrenato, I1
Sperati, F1
Barba, M1
Yosuico, VE1
Schünemann, H1
Akl, EA1
Levy, JH3
Faraoni, D1
Spring, JL1
Douketis, JD3
Samama, CM4
Schulman, S12
Kearon, C2
Kakkar, AK2
Schellong, S2
Eriksson, H2
Baanstra, D1
Kvamme, AM1
Friedman, J3
Mismetti, P3
Goldhaber, SZ3
Alikhan, R1
Rayment, R1
Keeling, D2
Baglin, T2
Benson, G1
Green, L1
Marshall, S1
Patel, R1
Pavord, S1
Rose, P1
Tait, C1
Berman, JP1
Halperin, JL4
Lenchus, JD1
Kasmeridis, C1
Lip, GY7
Apostolakis, S1
Dager, WE1
Gosselin, RC1
Roberts, AJ1
Southworth, MR2
Reichman, ME2
Unger, EF2
David, JS1
Piriou, V1
Albaladejo, P2
Hjemdahl, P1
Johnsson, H1
Wallén, NH1
Berger, R1
Salhanick, SD2
Chase, M1
Ganetsky, M2
Jacobson, BF1
Louw, S1
Büller, H1
Mer, M1
de Jong, PR1
Rowji, P1
Schapkaitz, E1
Adler, D1
Beeton, A1
Hsu, HC1
Wessels, P1
Haas, S1
Lisman, T1
Kamphuisen, PW2
Northup, PG1
Porte, RJ1
Andreev, DA1
Gappoeva, ZK1
Sychev, DA1
Giliarov, MIu1
Attia, JR1
Pearce, R1
Eikelboom, JW10
Hankey, GJ1
Chen, BC2
Sheth, NR1
Dadzie, KA1
Smith, SW2
Nelson, LS2
Hoffman, RS2
Winchester, JF1
Thigpen, JL1
Limdi, NA1
Pink, J1
Pirmohamed, M1
Hughes, DA1
Harris, K1
Mant, J1
Hesselbjerg, LJ1
Pedersen, HS1
Asmussen, MB1
Petersen, KD1
Yasaka, M2
Nutescu, EA2
Kalus, JS1
Healey, JS3
Eikelboom, J6
Yang, S6
Themeles, E3
Connolly, SJ13
Yusuf, S12
Douketis, J4
Wallentin, L11
Oldgren, J8
Heidbuchel, H3
Avezum, A3
Reilly, P4
Ezekowitz, M3
Ahmad, Y1
Steiner, T3
Böhm, M1
Dichgans, M1
Diener, HC5
Ell, C1
Endres, M1
Epple, C1
Grond, M1
Laufs, U1
Nickenig, G1
Riess, H1
Röther, J1
Schellinger, PD1
Spannagl, M1
Veltkamp, R1
Kawabata, M1
Yokoyama, Y1
Sasano, T1
Hachiya, H1
Tanaka, Y1
Yagishita, A1
Sugiyama, K1
Nakamura, T1
Suzuki, M1
Isobe, M1
Hirao, K1
Van Heukelom, J1
Lal, Y1
Sandhu, PS1
Wilson, C1
Dalton, E1
Bogdanov, A1
Hart, RG1
Ezekowitz, MD8
Reilly, PA5
Brueckmann, M4
Pogue, J1
Alings, M3
Amerena, JV1
Baumgartner, I1
Budaj, AJ1
Chen, JH1
Dans, AL1
Darius, H2
Di Pasquale, G1
Ferreira, J2
Flaker, GC1
Flather, MD1
Franzosi, MG2
Golitsyn, SP1
Halon, DA1
Hohnloser, SH3
Huber, K3
Jansky, P1
Kamensky, G3
Keltai, M1
Kim, SS1
Lau, CP1
Le Heuzey, JY2
Lewis, BS1
Liu, L1
Nanas, J1
Omar, R2
Pais, P1
Pedersen, KE1
Piegas, LS1
Raev, D1
Smith, PJ1
Talajic, M1
Tan, RS1
Tanomsup, S1
Toivonen, L1
Vinereanu, D1
Xavier, D1
Zhu, J1
Wang, SQ1
Duffy, CO1
Hapgood, G1
Butler, J1
Malan, E1
Chunilal, S1
Tran, H3
Pollack, CV2
Coyle, D2
Coyle, K1
Cameron, C2
Lee, K1
Kelly, S1
Steiner, S1
Wells, GA1
Boos, CJ1
Nam, M1
Camm, AJ1
Stöllberger, C1
Finsterer, J1
Lazo-Langner, A1
Lang, ES1
Fawole, A2
Daw, HA1
Crowther, MA3
Ferrandis, R1
Castillo, J1
de Andrés, J1
Gomar, C1
Gómez-Luque, A1
Hidalgo, F1
Llau, JV2
Sierra, P1
Torres, LM1
Shortt, B1
Robinson, M1
Steinberg, BA3
Kim, S1
Piccini, JP3
Fonarow, GC2
Lopes, RD1
Thomas, L2
Ansell, J3
Kowey, P1
Singer, DE3
Gersh, B2
Mahaffey, KW2
Hylek, E1
Go, AS3
Chang, P2
Peterson, ED2
Knauf, F1
Chaknos, CM1
Berns, JS1
Perazella, MA1
Assiri, A1
Al-Majzoub, O1
Kanaan, AO1
Donovan, JL1
Silva, M1
Djalali, S1
Weitz, JI4
Jennings, JM1
Robichaux, R1
McElderry, HT1
Plumb, VJ1
Gunter, A1
Doppalapudi, H1
Osorio, J1
Yamada, T1
Kay, GN1
Baumann Kreuziger, LM2
Reding, MT1
Zalesak, M1
Siu, K1
Francis, K1
Yu, C1
Alvrtsyan, H1
Rao, Y1
Walker, D1
Sander, S1
Miyasato, G1
Matchar, D1
Sanchez, H1
Avorn, J2
Majeed, A3
Ratanapo, S1
Ungprasert, P1
Srivali, N1
Cheungpasitporn, W1
Bischof, EF1
Thomas, PA1
Schaerf, NB1
Rosenfeld, JV1
Granger, CB3
Kappetein, AP1
Mack, MJ1
Blatchford, J1
Devenny, K1
Guiver, K1
Harper, R1
Khder, Y2
Lobmeyer, MT1
Maas, H1
Voigt, JU1
Simoons, ML1
Van de Werf, F2
Pernod, G2
Godier, A1
Susen, S1
Gruel, Y1
Blais, N1
Fontana, P2
Cohen, A2
Rosencher, N1
Schved, JF1
de Maistre, E1
Samama, MM1
Sié, P1
Castellucci, LA1
Le Gal, G1
Rodger, MA1
Wells, PS1
Clifford, T1
Gandara, E1
Wells, G1
Carrier, M2
Ryan, M1
Ware, K1
Qamri, Z1
Satoskar, A1
Wu, H1
Nadasdy, G1
Rovin, B1
Hebert, L1
Nadasdy, T1
Brodsky, SV1
Adam, SS1
McDuffie, JR1
Lachiewicz, PF1
Ortel, TL3
Williams, JW1
Pfeilschifter, W1
Luger, S1
Brunkhorst, R1
Lindhoff-Last, E1
Foerch, C2
Schaeffer, S1
Conway, SE3
Hwang, HG2
Fraessdorf, M2
Chandler, WL1
Blum, J1
Carreiro, S1
Hack, JB1
Díaz, MQ1
Borobia, AM1
Núñez, MA1
Virto, AM1
Fabra, S1
Casado, MS1
García-Erce, JA1
Pazmiño, P1
Yap, LB1
Rusani, BI1
Umadevan, D1
Muhammad, Z1
Hussin, A1
Kaur, S1
Holmes, DN1
Kowey, PR1
Hylek, EM3
Okada, Y1
Schaeffer, SE1
Harrison, DL1
Ragni, MV1
Clemens, A1
Noack, H1
van der Hulle, T1
Kooiman, J1
den Exter, PL1
Dekkers, OM1
Klok, FA1
Huisman, MV3
Verhamme, P2
Bounameaux, H2
Christiansen, AV1
Le Maulf, F1
Peter, N1
Aumann, V1
Boxberger, N1
Heim, MU1
Hartung, KJ1
Siegemund, A1
Herrmann, R1
Thom, J1
Wood, A1
Phillips, M1
Muhammad, S1
Baker, R1
Bachellerie, B1
Ruiz, S1
Conil, JM1
Crognier, L1
Seguin, T1
Georges, B1
Fourcade, O1
Ritchie, B1
Goy, JK1
Nahirniak, S1
Almutawa, M1
Ghanny, S1
Siegal, DM2
Garcia, DA3
Bloom, BJ1
Filion, KB1
Atallah, R1
Eisenberg, MJ1
Goto, S1
Tomita, A1
Kosiuk, J1
Koutalas, E1
Doering, M1
Sommer, P1
Rolf, S1
Breithardt, OA1
Nedios, S1
Dinov, B1
Hindricks, G1
Richter, S1
Bollmann, A1
Berthelot, E1
Lavenu-Bombled, C1
Orostegui-Giron, L1
Desconclois, C1
Assayag, P1
Miller, MP1
Trujillo, TC1
Nordenholz, KE1
Larsen, TB2
Gorst-Rasmussen, A1
Rasmussen, LH2
Skjøth, F2
Rosenzweig, M1
Molinier, A1
Acket, B1
Bourrel, R1
Lavezzi, O1
Montastruc, JL1
Bagheri, H1
Joson, J1
Nguyen, VT1
Shah, R1
Schaefer, JH1
Leung, W1
Wu, L1
Van Cott, EM1
Lok, J1
Whalen, M1
van Leyen, K1
Lauer, A1
van Ryn, J1
Lo, EH1
Providência, R1
Marijon, E1
Albenque, JP1
Combes, S1
Combes, N1
Jourda, F1
Hireche, H1
Morais, J1
Boveda, S1
Capodanno, D1
Angiolillo, DJ1
Brunetti, L1
Chen, C1
White, J1
Wong, H1
Antoniazzi, S1
Berdaï, D1
Conti, V1
Clementi, E1
Salvo, F1
McConeghy, KW1
Bress, A1
Qato, DM1
Wing, C1
Thachil, J2
Fenger-Eriksen, C1
Münster, AM1
Grove, EL1
Gallus, A1
Poller, L1
Jespersen, J1
Ibrahim, S1
Lai, A1
Davidson, N1
Galloway, SW1
Brieger, D1
Steurer, J2
Granziera, S1
Cohen, AT1
Dempfle, CE1
Noll, G1
Noll, S1
Hürlimann, D1
Fontaine, GV1
Mathews, KD1
Woller, SC1
Stevens, SM1
Lloyd, JF1
Evans, RS1
Shore, S1
Carey, EP1
Turakhia, MP2
Jackevicius, CA1
Cunningham, F1
Pilote, L1
Bradley, SM1
Maddox, TM1
Grunwald, GK1
Barón, AE1
Rumsfeld, JS1
Varosy, PD1
Schneider, PM1
Marzec, LN1
Ho, PM1
Sølbeck, S1
Nilsson, CU1
Engström, M1
Ostrowski, SR1
Johansson, PI1
Lévy, S1
Joseph, J1
Young, L2
McRae, S1
Curnow, J1
Nandurkar, H1
Wood, P1
McLintock, C2
Gómez-Outes, A1
Terleira-Fernández, AI1
Lecumberri, R1
Suárez-Gea, ML1
Vargas-Castrillón, E1
Cohen, D2
Charlton, B1
Redberg, R1
Alotaibi, G1
Alsaleh, K1
Wu, C1
Mcmurtry, MS1
Moore, TJ1
Cohen, MR1
Mattison, DR1
Sardar, P2
Chatterjee, S2
Herzog, E1
Nairooz, R1
Mukherjee, D2
Amin, A2
Jing, Y1
Trocio, J1
Lin, J1
Lingohr-Smith, M1
Graham, J1
Ho, MH1
Ho, CW1
Cheung, E1
Chan, PH1
Hai, JJ1
Chan, KH1
Chan, EW1
Leung, GK1
Tse, HF1
Siu, CW1
Vaughan Sarrazin, MS1
Jones, M1
Mazur, A1
Chrischilles, E1
Cram, P1
Badal, M1
Aryal, MR1
Mege, J1
Chaudhary, A1
Donato, AA1
DeFelipe-Mimbrera, A1
Alonso Cánovas, A1
Guillán, M2
Matute, C1
Sainz de la Maza, S1
Cruz, A1
Vera, R1
Masjuan, J2
Stokes, M1
Makenbaeva, D1
Wiederkehr, D1
Wu, N1
Lawrence, JH1
Keenan, JC1
Morton, CT1
Dries, DJ1
Kyrle, PA1
Binder, K1
Eichinger, S1
Függer, R1
Gollackner, B1
Hiesmayr, JM1
Lang, W1
Perger, P1
Quehenberger, P1
Roithinger, FX1
Schmaldienst, S1
Weltermann, A1
Domanovits, H1
Rudakova, AV1
Tatarskiĭ, BA1
Hifumi, T1
Takada, H1
Kiriu, N1
Pugi, A1
Fallani, F1
Palazzi, N1
Banfi, R1
Pluym, M1
Howell, G1
Graham, DJ1
Wernecke, M1
Zhang, R1
Levenson, M1
Sheu, TC1
Mott, K1
Goulding, MR1
Houstoun, M1
MaCurdy, TE1
Worrall, C1
Kelman, JA1
Redberg, RF1
Hernandez, I2
Baik, SH1
Piñera, A1
Zhang, Y2
Baber, U1
Mastoris, I1
Mehran, R1
Beyer-Westendorf, J1
Snipelisky, D2
Ray, JC1
Ung, R1
Duart, M1
Kauffman, C2
Kusumoto, F2
Bell, AD2
Liew, A1
Carney, EF1
Getta, B1
Muller, N1
Motum, P1
Hsu, D1
Zebeljan, D1
Rosenfeld, D1
Lavie, CJ1
Giri, JS1
Ghosh, J1
Owada, S1
Tomita, H1
Kinjo, T1
Ishida, Y1
Itoh, T1
Sasaki, K1
Horiuchi, D1
Kimura, M1
Sasaki, S1
Okumura, K1
Davis, EM1
Uhlmeyer, EM1
Schmidt, DP1
Schardt, GL1
Beliavskaia, OO1
Vavilova, TV1
Cairns, JA1
Hoffman, M1
Volovyk, Z1
Monroe, DM1
Peacock, WF1
Armbruster, HL1
Lindsley, JP1
Moranville, MP1
Habibi, M1
Khurram, IM1
Spragg, DD1
Berger, RD1
Calkins, H1
Marine, JE1
Gorzelak-Pabiś, P1
Duraj, I1
Szlagowska, L1
Ciastkowska, A1
Broncel, M1
Sukovatykh, BS1
Belikov, LN1
Savchuk, OF1
Sukovatykh, MB1
Blann, AD1
Moustafa, F1
Milhaud, G1
Dublanchet, N1
Lebreton, A1
Dutheil, F1
Schmidt, J1
Chan, KE1
Edelman, ER1
Wenger, JB1
Thadhani, RI1
Maddux, FW1
Karetová, D1
Bultas, J2
Rockey, DC1
Hasler, S1
Bouchard, J1
Ghannoum, M1
Bernier-Jean, A1
Williamson, D1
Kershaw, G1
Weatherburn, C1
Eris, JM1
Patel, JP2
Roberts, DM1
Liotta, EM1
Levasseur-Franklin, KE1
Naidech, AM1
Kim, B1
Patel, AD1
Tan, MK1
Angaran, P1
Berall, M1
Bucci, C1
Demchuk, AM1
Essebag, V1
Goldin, L1
Green, MS1
Gregoire, JC1
Gross, PL1
Heilbron, B1
Lin, PJ1
Ramanathan, K1
Skanes, A1
Wheeler, BH1
Goodman, SG1
Oberhofer, E1
Messerschmidt, C1
Friedman, RJ2
Lane, DA3
Wood, K1
Gehrie, E1
Tormey, C1
Lee, AY1
Shivakumar, S1
Blostein, M1
Spencer, FA2
Solymoss, S1
Barty, R1
Wang, G1
Heddle, N1
Nagao, T1
Inden, Y1
Shimano, M1
Fujita, M1
Yanagisawa, S1
Kato, H1
Ishikawa, S1
Miyoshi, A1
Okumura, S1
Ohguchi, S1
Yamamoto, T1
Yoshida, N1
Hirai, M1
Murohara, T1
Chang, TW1
Arpey, CJ1
Baum, CL1
Brewer, JD1
Hochwalt, PC1
Hocker, TL1
Roenigk, RK1
Otley, CC1
Bauer, KA1
Glund, S1
Bernstein, RA1
Dubiel, R1
Kreuzer, J2
Sellke, FW1
Stangier, J1
Wang, B1
Kam, CW1
Miyares, MA2
Horjus, DL1
van Montfrans, GA1
Brewster, LM1
Klil-Drori, A1
Azoulay, L1
Zint, K1
Liu, S1
Kim, CO1
Lucyk, SN1
Henriksen, DP1
Hansen, MR1
Damkier, P1
Zeus, T1
Kelm, M1
Bode, C1
Lavine, JB1
Torjesen, I1
Heard, LK1
Shanahan, C1
Maggio, KL1
Escobar, C2
Barrios, V2
Jimenez, D1
Romualdi, E1
Rancan, E1
Siragusa, S2
Ageno, W1
Quinlan, DJ1
Dahl, OE3
Freeman, JV1
Zhu, RP1
Owens, DK1
Garber, AM1
Hutton, DW1
Wang, PJ1
Oliver, M1
Loke, YK1
Kwok, CS1
Nagarakanti, R1
Chernick, M1
Aikens, TH1
Flaker, G1
Brugada, J1
Parekh, A1
Eriksson, BI1
Huo, MH1
Kurth, AA1
Hantel, S1
Hermansson, K1
Schnee, JM1
Hori, M1
Beasley, BN1
Temple, R1
Matute, MC1
García-Caldentey, J1
Buisan, J1
Aparicio, M1
Alonso de Leciñana, M1
Budaj, A1
Roberts, J1
Siegbahn, A1
Tijssen, JG1
Kaatz, S2
Varrone, J1
Shah, SV1
Gage, BF1
Welzel, D1
Hull, R1
Fareed, J1
Lee, TH1
Kazmi, RS1
Lwaleed, BA1
Gage, L1
Roberts, LN1
Arya, R1
Babu, KM1
Brown, RS1
Boyer, EW1
Hunchuck, JE1
Lake, JD1
Pengo, V2
Crippa, L2
Falanga, A2
Finazzi, G2
Marongiu, F2
Palareti, G2
Poli, D2
Testa, S2
Tiraferri, E2
Tosetto, A2
Tripodi, A3
Manotti, C2
Winkle, RA1
Mead, RH1
Engel, G1
Kong, MH1
Patrawala, RA1
Weimar, C1
Augoustides, JG1
Jolobe, OM1
Beyth, RJ1
Landefeld, CS1
Cotton, BA1
McCarthy, JJ1
Holcomb, JB1
Panchenko, EP1
Moore, CH1
Snashall, J1
Boniface, K1
Scott, J1
Govindarajan, R1
Salgado, E1
Reynolds, S1
Parra, D1
Rosenstein, RS1
Reiffel, JA1
Suzuki, S1
Otsuka, T1
Sagara, K1
Matsuno, S1
Funada, R1
Uejima, T1
Oikawa, Y1
Yajima, J1
Koike, A1
Nagashima, K1
Kirigaya, H1
Sawada, H1
Aizawa, T1
Yamashita, T1
Tendera, M1
Syzdół, M1
Parma, Z1
Lakkireddy, D1
Reddy, YM1
Di Biase, L1
Vanga, SR1
Santangeli, P1
Swarup, V1
Pimentel, R1
Mansour, MC1
D'Avila, A1
Sanchez, JE1
Burkhardt, JD1
Chalhoub, F1
Mohanty, P1
Coffey, J1
Shaik, N1
Monir, G1
Reddy, VY1
Ruskin, J1
Natale, A1
You, JJ1
Howard, PA1
Eckman, MH1
Fang, MC1
Hughes, M1
Manning, WJ1
Lip, GYH1
Comin, J1
Kallmes, DF1
Soff, GA1
Harper, P2
Merriman, E1
Ali, A1
Bailey, C1
Abdelhafiz, AH1
Cano, EL1
Drost, P1
Marchant, N1
Mitchell, S1
Orme, M1
Rublee, D1
Simon, TA1
Sutton, A1
Nieto, JA1
Espada, NG1
Merino, RG1
González, TC1
Baker, RI1
Schomburg, JL1
Medina, EM1
Lahti, MT1
Bianco, RW1
Mustonen, P1
Puurunen, M1
Ilmakunnas, M1
Louhimo, J1
Lassila, R1
Varughese, CJ1
Lewalter, T1
Little, JW1
Gil Núñez, A1
Zapata Wainberg, G1
Ximénez-Carrillo Rico, A1
Vivancos Mora, J1
Heidbuchle, H1
Kar, S1
Bhatt, DL1
Mantha, S1
Radecki, RP1
Schneeweiss, S1
Gagne, JJ1
Patrick, AR1
Choudhry, NK1
Bilen, O1
Teruya, J1
Moia, M1
Huang, C1
Siu, M1
Vu, L1
Wong, S1
Shin, J1
Shevelev, VI2
Kanorskiĭ, SG1
Husari, A1
Beydoun, A1
Sheik Ammar, A1
Maakaron, JE1
Taher, A1
Prussak, K1
Johns, G1
Venkatachalam, K1
Kosar, L1
Jin, M1
Kamrul, R1
Schuster, B1
Alonso-Coello, P1
Zhou, Q1
Guyatt, G1
Spyropoulos, AC1
Gerotziafas, G1
Viny, AD1
Garlich, FM1
Basciano, P1
Howland, MA1
Yokoi, K1
Isoda, K1
Kimura, T1
Adachi, T1
Harenberg, J1
Marx, S1
Marder, VJ1
Schulze, A1
Wehling, M1
Weiss, C1
Ehrenschwender, M1
Koessler, J1
Brunner, K1
Steigerwald, U1
Esmon, CT1
Kawaguchi, K1
Lambein, F1
Kusama-Eguchi, K1
Tafur, A1
Wysokinski, WE1
McBane, RD1
Aalbers, J1
Hardy, G1
Furman, NV1
Kuvshinova, LE1
Dovgalevskiĭ, IaP1
Obeng-Gyasi, S1
Loor, MM1
Samotowka, MA1
Moorman, ML1
Pieracci, FM1
Haschke, M1
Pisters, R1
Nieuwlaat, R1
Crijns, HJ1
Pawlikowska, Z1
Szponar, J1
Kanorsky, SG1
Deitelzweig, SB1
Best, M1
Palmer, K1
Jones, QC1
Wathen, CG1
Huang, GS1
Chance, EA1
Gómez Arrayas, I1
Suárez Fernández, C1
Gómez Cerezo, JF1
Betegón Nicolás, L1
de Salas-Cansado, M1
Rubio-Terrés, C1
Livio, F1
Brem, E1
Koyfman, A1
Foran, M1
Breik, O1
Tadros, R1
Devitt, P1

Clinical Trials (34)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prothrombin Complex Concentrate (PCC) Compared to Fresh Frozen Plasma (FFP) for Post-cardiopulmonary Bypass Coagulopathy and Bleeding, a Prospective Randomized Trial at Large US Medical Center.[NCT02557672]Phase 4106 participants (Actual)Interventional2016-08-31Completed
Investigation of Genetic Variations on Patients With Adverse Events While on Direct Oral Anticoagulants (DOACs)[NCT04580589]210 participants (Actual)Observational2021-02-01Completed
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.[NCT00558259]Phase 31,353 participants (Actual)Interventional2007-11-30Completed
A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembo[NCT00329238]Phase 32,867 participants (Actual)Interventional2006-05-31Completed
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis[NCT04981327]Phase 31,300 participants (Anticipated)Interventional2022-09-01Not yet recruiting
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600]Phase 318,113 participants (Actual)Interventional2005-12-31Completed
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes[NCT00808067]Phase 35,897 participants (Actual)Interventional2008-11-30Completed
An Epidemiological Study to Evaluate the Use of Vitamin K Antagonists and New Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients in Turkey[NCT02354456]4,100 participants (Anticipated)Observational [Patient Registry]2015-01-31Recruiting
Prospective Observational Study of the Direct Oral Anticoagulants Periprocedural Management[NCT03182218]1,100 participants (Actual)Observational2015-02-28Completed
Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm (BOAT OAR)[NCT03515083]100 participants (Actual)Interventional2017-07-17Completed
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)[NCT01165710]10,179 participants (Actual)Observational2010-06-30Completed
This is a Prospective, Open-label Phase 2 Pilot Study With Independent Evaluation of All Outcomes and a Historical Control Group to Determine if Rivaroxaban (Xarelto) is Feasible and Safe for Prevention of Major Complications in Patients Undergoing a Mech[NCT02128841]Phase 212 participants (Actual)Interventional2012-09-30Terminated (stopped due to not enough patients)
A Prospective, Randomized, Active (Warfarin) Controlled, Parallel-arm Clinical Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely and Effectively on Apixaban[NCT04142658]Phase 3863 participants (Actual)Interventional2020-05-01Terminated (stopped due to Safety)
Pharmacogenetic Algorithm of Response to Warfarin During Initial Anticoagulation in Chinese Elderly Patients[NCT02211326]660 participants (Actual)Interventional2014-09-01Completed
Evaluation of the Long Term Safety of the Use of Dabigatran Etexilate in Patients With a Bileaflet Mechanical Heart Valve[NCT01505881]Phase 2158 participants (Actual)Interventional2011-12-31Terminated
A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt[NCT01452347]Phase 2328 participants (Actual)Interventional2011-10-31Terminated
Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?[NCT02900170]8 participants (Actual)Observational2016-07-31Completed
A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatm[NCT00680186]Phase 32,589 participants (Actual)Interventional2008-04-30Completed
A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following In[NCT00291330]Phase 32,564 participants (Actual)Interventional2006-02-28Completed
The Prevalence of Post-Thrombotic Syndrome in Deep-Vein Thrombosis (DVT) Patients Treated With Dabigatran- a Cross-Sectional Assessment of RE-COVER Study Patients[NCT03050138]351 participants (Actual)Observational2016-04-30Completed
Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation: a Randomized, Multi-center, Parallel-group Trial (PILOT)[NCT03433235]Phase 268 participants (Actual)Interventional2018-06-19Completed
Effectivity of a Joint Didactic Intervention by School for Patients on Inappropriate Control Prothrombin Time Anticoagulated Patients. Protocol for Developing a Randomized and Controlled Clinical Trial[NCT03647254]1 participants (Anticipated)Interventional2018-09-01Recruiting
A Monitor System for the Safety of Dabigatran Anticoagulation Treatment in Nonvalvular Atrial Fibrillation[NCT02414035]1,496 participants (Actual)Observational2015-03-22Completed
Pilot Intervention to Improve Adherence to Dabigatran for Patients With Atrial Fibillation[NCT01578044]12 participants (Actual)Interventional2012-01-31Completed
Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288]1,200 participants (Anticipated)Interventional2020-12-16Active, not recruiting
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial[NCT02942407]Phase 4154 participants (Actual)Interventional2016-12-31Completed
A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emerge[NCT02104947]Phase 3503 participants (Actual)Interventional2014-05-06Completed
A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Comp[NCT00657150]Phase 32,055 participants (Actual)Interventional2008-03-31Completed
CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295]1,000 participants (Anticipated)Observational [Patient Registry]2018-05-01Recruiting
Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777]4,162 participants (Actual)Observational2014-04-30Completed
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928]Phase 3200 participants (Actual)Interventional2017-06-14Active, not recruiting
Anticoagulant-associated Intracranial Hemorrhage: Patient Characteristics and Outcomes From National Institute of Neurology and Neurosurgery Manuel Velasco: Single-Center Observational Study[NCT06168838]1,200 participants (Anticipated)Observational2023-08-09Recruiting
Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study[NCT03181386]Phase 360 participants (Actual)Interventional2017-05-03Completed
Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants[NCT02185027]1,166 participants (Actual)Observational2013-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Chest Tube Output

The amount of chest tube drainage output from after surgery through midnight of the next day. As measured in mL. (NCT02557672)
Timeframe: 24 hours

InterventionmL (Median)
Fresh Frozen Plasma1022
Prothrombin Complex Concentrate937

Cryoprecipitate (Cryo) Blood Product Transfusion

The number of subject's who received 0,1,2,3 or more units of Cryo's transfused from completion of study drug administration though midnight of the next day. (NCT02557672)
Timeframe: 24 hours

,
InterventionParticipants (Count of Participants)
0 units1 unit2 units3 or more units
Fresh Frozen Plasma40251
Prothrombin Complex Concentrate40281

Fresh Frozen Plasma (FFP) Blood Product Transfusion

The number of subject's who received 0,1,2,3 or more units of FFP's transfused from completion of study drug administration though midnight of the next day. (NCT02557672)
Timeframe: 24 hours

,
InterventionParticipants (Count of Participants)
0 units1 unit2 units3 or more units
Fresh Frozen Plasma43041
Prothrombin Complex Concentrate48120

Platelets Blood Product Transfusion

The number of subject's who received 0,1,2,3 or more units of Platelets transfused from completion of study drug administration though midnight of the next day. (NCT02557672)
Timeframe: 24 hours

,
InterventionParticipants (Count of Participants)
0 units1 unit2 units3 or more units
Fresh Frozen Plasma301332
Prothrombin Complex Concentrate36933

Red Blood Cell (RBC) Blood Product Transfusion

The number of subject's who received 0,1,2,3 or more units of RBC's transfused from completion of study drug administration though midnight of the next day. (NCT02557672)
Timeframe: 24 hours

,
InterventionParticipants (Count of Participants)
0 units1 unit2 units3 or more units
Fresh Frozen Plasma261165
Prothrombin Complex Concentrate36852

Centrally Confirmed Cardiovascular Events During the Treatment Period

Cardiovascular events that occurred during the treatment period + 3 days were summarised by treatment groups. (NCT00558259)
Timeframe: 6 months

Interventionparticipants (Number)
Dabigatran3
Placebo2

Centrally Confirmed Symptomatic Pulmonary Embolism (PE) Events During the Intended Treatment Period

Number of participants with centrally confirmed symptomatic pulmonary embolism (PE) events during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months

InterventionParticipants (Number)
Dabigatran1
Placebo14

Centrally Confirmed Symptomatic Recurrent Deep Venous Thrombotic (DVT) Events During the Intended Treatment Period

Number of the participants with centrally confirmed symptomatic recurrent deep venous thrombotic (DVT) events during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months

InterventionParticipants (Number)
Dabigatran2
Placebo23

Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Excluding Unexplained Death During the Intended Treatment Period

Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event. (NCT00558259)
Timeframe: 6 months

InterventionParticipants (Number)
Dabigatran3
Placebo35

Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period

Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event. (NCT00558259)
Timeframe: 6 months

InterventionParticipants (Number)
Dabigatran3
Placebo37

Centrally Confirmed Unexplained Deaths During the Intended Treatment Period

Number of participants with centrally confirmed unexplained deaths during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months

Interventionparticipants (Number)
Dabigatran0
Placebo2

Centrally Confirmed Bleeding Event During the Treatment Period

"Major bleeding events (MBE) had to fulfil at least 1 of the following criteria:~Fatal bleeding~Associated with a fall in haemoglobin of ≥2 g/dL~Led to the transfusion of ≥2 units packed cells or whole blood~Occurred in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal~Other clinically relevant bleeding was defined as overt bleeding not meeting the criteria for an MBE but associated with medical intervention, unscheduled contact with a physician, (temporary) cessation of study treatment, or associated with discomfort such as pain, or impairment of activities of daily life.~Examples of these bleedings were:~Bleeding that compromised haemodynamics~Bleeding that led to hospitalisation~Trivial bleeding events were defined as all other bleeding events that did not fulfil the criteria of MBEs or CRBEs.~All bleeding events include MBEs, CRBEs, and trivial bleeding events." (NCT00558259)
Timeframe: 6 months

,
Interventionparticipants (Number)
MBEMBE or CRBEAll Bleeding
Dabigatran23672
Placebo01239

Laboratory Measures, Especially Liver Function Tests (LFTs)

Number of participants with possible clinically significant abnormalities during the treatment period. (NCT00558259)
Timeframe: 6 months

,
Interventionparticipants (Number)
AST increase (N=655, 629)ALT increase (N=655, 629)Alkaline phosphatase increase (N=658, 629)Total bilirubin increase (N=658, 628)
Dabigatran2301
Placebo2501

Composite of Recurrent VTE or All Cause Death at 18 Months

Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. (NCT00329238)
Timeframe: 18 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran361394
Warfarin321394

Composite of Recurrent VTE or All Cause Death at 36 Months

Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. (NCT00329238)
Timeframe: 36 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran421388
Warfarin361390

Composite of Recurrent VTE or VTE Death at 18 Months

Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE. (NCT00329238)
Timeframe: 18 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran221408
Warfarin171409

Composite of Recurrent VTE or VTE Death at 36 Months

Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE. (NCT00329238)
Timeframe: 36 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran261404
Warfarin181408

Deaths of All Causes at 18 Months

Deaths of all causes at 18 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments. (NCT00329238)
Timeframe: 18 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran151415
Warfarin161410

Deaths of All Causes at 36 Months

Deaths of all causes at 36 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments. (NCT00329238)
Timeframe: 36 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran171413
Warfarin191407

Deaths Related to VTE at 18 Months

Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way. (NCT00329238)
Timeframe: 18 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran11429
Warfarin11425

Deaths Related to VTE at 36 Months

Deaths related to VTE (i.e. fatal PE) at 36 Months. Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way. (NCT00329238)
Timeframe: 36 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran11429
Warfarin11425

Deep Vein Thrombosis (DVT) at 36 Months

Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation. (NCT00329238)
Timeframe: 36 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran171413
Warfarin131413

DVT at 18 Months

Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation. (NCT00329238)
Timeframe: 18 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran151415
Warfarin121414

Laboratory Analysis

Patients with LFT (liver function tests) increases of possible clinical significance during treatment. Increases of possible clinical significance were defined as: ≥3 x ULN (AST, ALT), ≥2 x ULN (AP), and ≥2 mg/dL (total bilirubin). Only patients with a baseline value which was not of possible clinical significance (or without any baseline value) could have a PCSA (Possible clinically significant abnormality). (NCT00329238)
Timeframe: 18 months + 30 days follow up

,
Interventionparticipants (Number)
ALT increaseAST increaseAlkaline phosphataseTotal bilirubin
Dabigatran262399
Warfarin3023148

Number of Participants With Bleeding Events

"MBE (major bleeding event) if it fulfilled at least one of the following criteria~Fatal bleeding~Symptomatic bleeding in a critical area or organ.~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.~Minor bleeding event was any bleeding that did not fulfil any of the criteria for MBEs~CRBE (clinically relevant bleeding event) if it is a minor bleeding events which fulfilled at least one of the following criteria~Spontaneous skin haematoma ≥25 cm2~Spontaneous nose bleed >5 min duration~Macroscopic haematuria, either spontaneous or, if associated with an intervention, lasting >24 h~Spontaneous rectal bleeding~Gingival bleeding >5 min~Bleeding leading to hospitalisation or requiring surgical treatment~Bleeding leading to a transfusion of <2 units of whole blood or red cells~Any other bleeding event considered clinically relevant by the investigator" (NCT00329238)
Timeframe: first intake of study drug until 6 days following last intake of study drug

,
Interventionparticipants (Number)
patients with MBEpatients with MBE and /or CRBEpatients with any bleeding event
Dabigatran1380277
Warfarin25145373

Number of Participants With Definite Acute Coronary Syndrome (ACS)

All suspected ACS occurring during the trial were to be recorded on the CRF and were to be centrally adjudicated by an independent ACS/AC in a treatment-blinded manner. (NCT00329238)
Timeframe: day of first study drug intake until last day of study drug intake; from the day after last intake of study drug until trial termination

,
Interventionparticipants (Number)
During intake of study drug, N=1430 , N=1415After stopping study drug, N=1426, N=1400
Dabigatran121
Warfarin25

Symptomatic Pulmonary Embolism (PE) at 18 Months

Symptomatic pulmonary embolism (PE) at 18 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography. (NCT00329238)
Timeframe: 18 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran81422
Warfarin51421

Symptomatic Pulmonary Embolism (PE) at 36 Months

Symptomatic pulmonary embolism (PE) at 36 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography. (NCT00329238)
Timeframe: 36 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran101420
Warfarin51421

Abnormal Liver Function Test

Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months

Interventionparticipants (Number)
Dabigatran 110 mg11
Dabigatran 150 mg14
Warfarin21

Yearly Event Rate for Composite Endpoint of Stroke/SEE

Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg1.54
Dabigatran 150 mg1.11
Warfarin1.71

Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death

Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg4.85
Dabigatran 150 mg4.32
Warfarin5.20

Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death

Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg4.26
Dabigatran 150 mg3.68
Warfarin4.35

Bleeding Events (Major and Minor)

"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months

,,
Interventionyearly event rate (percentage) (Number)
Major bleedsMinor bleeds
Dabigatran 110 mg2.9913.16
Dabigatran 150 mg3.5514.85
Warfarin3.8116.37

Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)

Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months

,,
Interventionyearly event rate (percentage)] (Number)
intracerebral hemorrhageintracranial hemorrhage (ICH)
Dabigatran 110 mg0.120.23
Dabigatran 150 mg0.100.32
Warfarin0.380.76

Acute Myocardial Infarction (MI), Annualized Rate of Subjects With MI

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~a. In subjects not undergoing PCI or CABG a subject should have fulfilled at least 2 of the following: i. Typical prolonged severe chest pain or related symptoms or signs suggestive of MI. ii. Elevation of troponin or CK-MB to more than upper level of normal (ULN) or, if CK-MB was elevated at baseline, re-elevation to more than 50% increase above the previous level. iii. Development of significant Q-waves in at least 2 adjacent ECG leads. b. After percutaneous coronary intervention (within 24h). c. After coronary artery bypass grafting (within 72h). d. Silent myocardial infarction. e. Myocardial infarction could also have been demonstrated at autopsy." (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg0.72
Dabigatran 150 mg0.66

Annualized Rate of Subjects With Any Bleeds (Major Plus Minor)

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg9.44
Dabigatran 150 mg11.20

Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE)

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg1.60
Dabigatran 150 mg1.47

Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE) and All Cause Death

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg4.40
Dabigatran 150 mg4.02

Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction (MI), All Cause Death and Major Bleed

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg6.65
Dabigatran 150 mg7.14

Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction, Vascular Death

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg3.51
Dabigatran 150 mg3.32

Annualized Rate of Subjects With Intra-Cranial Hemorrhage (ICH)

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg0.28
Dabigatran 150 mg0.33

Annualized Rate of Subjects With Minor Bleeds

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Minor bleeds were clinical bleeds that did not fulfill the criteria for major bleeds. Minor bleeds were classified as associated with study medication discontinuation (temporary or permanent) or not." (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg7.49
Dabigatran 150 mg8.98

Death, Annualized Rate of Subject Death

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Deaths were classified as being vascular (sudden/arrhythmic, pump failure death, or other vascular, including bleeding) or non-vascular, due to other specified causes (e.g., malignancy), or of unknown etiology." (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg3.18
Dabigatran 150 mg2.99

Deep Vein Thrombosis, Annualized Rate of Subjects With DVT

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Deep Vein Thrombosis (DVT) was generally documented by one of the following:~abnormal compression ultrasound (CUS),~an intraluminal filling defect on venography." (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg0.06
Dabigatran 150 mg0.11

Major Bleeding, Annualized Rate of Subjects With Major Bleeds

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Major bleeding must have satisfied one or more of the following criteria:~Bleeding associated with a reduction in hemoglobin of at least 20 g/L~Required transfusion of at least 2 units of blood or packed cells~Symptomatic bleeding in a critical area or organ: intraocular, intraspinal, intramuscular with compartment syndrome, retroperitoneal, intra-articular, pericardial, gastrointestinal~Major bleed were classified as life-threatening if they met one or more of the following criteria:~Reduction in hemoglobin of at least 50 g/L~Transfusion of at least 4 units of blood or packed cells~Symptomatic intracranial bleeding, either subdural or intracerebral~Associated with hypotension requiring use of intravenous inotropic agents~Required surgical intervention to stop bleeding~Resulted in death" (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg2.79
Dabigatran 150 mg3.59

Non CNS Systemic Embolism (SEE), Annualized Rate of Subjects With Non-CNS SEE

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Systemic embolism was an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts), and was to be documented by angiography, surgery, scintigraphy, or autopsy." (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg0.25
Dabigatran 150 mg0.23

Pulmonary Embolism (PE), Annualized Rate of Subjects With PE

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Pulmonary Embolism was generally documented by one of the following:~an intraluminal filling defect in segmental or more proximal branches on spiral CT scan~an intraluminal filling defect or an extension of an existing defect or a sudden cutoff of vessels more than 2.5 mm in diameter on the pulmonary angiogram~a perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS)~inconclusive spiral CT, pulmonary angiography or lung scintigraphy with demonstration of DVT in the lower extremities by compression ultrasound or venography." (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg0.10
Dabigatran 150 mg0.12

Stroke, Annualized Rate of Subjects With Stroke

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Stroke was an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke was categorized as ischemic or hemorrhagic or cause unknown based on computerized tomography (CT), magnetic resonance (MR) scanning or autopsy. Fatal stroke was defined as death from any cause within 30 days of stroke. Severity of stroke was assessed by modified Rankin score at discharge from hospital" (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg1.39
Dabigatran 150 mg1.26

Percentage of Patients With AEs Leading to Discontinuation of Trial Drug

"Percentage of patients with Adverse Events leading to discontinuation of trial drug.~Prespecified clinical outcome events were not recorded as Adverse Events." (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)

Interventionpercentage of participants (Number)
Dabigatran Etexilate (DE)5.1
Warfarin1.7

Percentage of Patients With Any Adverse Event (AE)

Percentage of patients with Adverse Events. Prespecified clinical outcome events were not recorded as Adverse Events. (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)

Interventionpercentage of participants (Number)
Dabigatran Etexilate (DE)39.4
Warfarin37.3

Percentage of Patients With Serious AEs

Percentage of patients with Serious Adverse Events (SAE). Prespecified clinical outcome events were not recorded as Adverse Events. (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)

Interventionpercentage of participants (Number)
Dabigatran Etexilate (DE)3.0
Warfarin6.8

Percentage of Deaths, Venous Thromboembolism (VTE), Myocardial Infarction (MI), Transient Ischaemic Attacks (TIA), Strokes, Systemic Embolism, and Valve Thrombosis.

"Clinical efficacy outcome events presented are:~Death, Venous thromboembolism (VTE), Myocardial Infarction (MI), Transient Ischaemic Attack (TIA), Stroke, Systemic embolism and Valve thrombosis" (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)

,
Interventionpercentage of participants (Number)
DeathVenous thromboembolismMyocardial InfarctionTransient Ischaemic AttackStrokeSystemic embolismValve thrombosis
Dabigatran Etexilate (DE)0.00.01.01.03.00.02.0
Warfarin1.70.00.00.00.00.00.0

Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at End of Trial (EoT) at Week 12

"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~(As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients)~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 12

Interventionng/mL (Geometric Mean)
Observed108.21
Predicted104.80

Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 2

"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 2

Interventionng/mL (Geometric Mean)
Observed84.08
Predicted99.55

Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 4

"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 4

Interventionng/mL (Geometric Mean)
Observed104.43
Predicted109.36

Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations at Steady State (C Trough,ss) at Week 1

"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE) .~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 1

Interventionng/mL (Geometric Mean)
Observed73.86
Predicted99.52

Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at End of Trial (EoT) Week 12

Percentage of patients with observed Ctrough,ss value < 50 ng/mL (As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients) This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 12

Interventionpercentage of participants (Number)
Patients Evaluated7.4

Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 1

Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 1

Interventionpercentage of participants (Number)
Patients Evaluated26.9

Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 2

Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 2

Interventionpercentage of participants (Number)
Patients Evaluated19.2

Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 4

Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 4

Interventionpercentage of participants (Number)
Patients Evaluated9.8

Incidence of Anticoagulant-related Nephropathy in the Cohort

Primary endpoint - Incidence of ARN is the primary outcome of this study and this is based on a documentation of AKI (defined as an increase in baseline serum creatinine ≥ 0.3 mg/dL), in the absence of any other obvious etiology for the AKI identified after a standard clinical evaluation and work up by the patient's primary care physician, cardiologist or nephrologist. This incidence will be expressed as a percentage. (NCT02900170)
Timeframe: 6 months

InterventionPercentage of participants (Number)
Participants0

Laboratory Analyses

Frequency of patients with possible clinically significant abnormalities. (NCT00680186)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout

,
Interventionparticipants (Number)
AST increaseAST decreaseALT increaseALT decreaseBilirubin increaseBilirubin decrease
Dabigatran 150 mg29031080
Warfarin27040060

Number of Participants Who Died (Any Cause)

Any deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg2529
Warfarin2526

Number of Participants Who Died Due to VTE

VTE - related deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. Hazard ratios and 95% CI were not calculated because of insufficient number of events. (NCT00680186)
Timeframe: From randomisation to 6 months (up to day 180) and to end of ptp (planned to be up to day 224)

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg33
Warfarin00

Number of Participants With Acute Coronary Syndrome (ACS)

Any ACS occurring during the conduct of the study (centrally adjudicated as definite). Patients having a centrally adjudicated definite ACS during intake of study drug and after stopping study drug, according to treatment group. ACS assessments pre-specified in the protocol without adjudication. Prior to database lock, the steering committee asked to have ACS events adjudicated by an independent committee. After database lock, the committee was provided with source documentation that was blinded to the patient's treatment assignment. ACS results presented are based on adjudication findings. (NCT00680186)
Timeframe: From first intake of study drug to last contact date

,
Interventionparticipants (Number)
During intake of study drugAfter stopping study drug
Dabigatran 150 mg32
Warfarin01

Number of Participants With MBE, MBE and/or CRBE, and Any Bleeding Events

"Major bleeding events (MBE) are defined as~Fatal bleeding~Symptomatic bleeding in a critical area or organ~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells~Clinically-relevant bleeding events (CRBE) are defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~leading to hospitalisation and / or requiring surgical treatment~leading to a transfusion of <2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00680186)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout

,
Interventionparticipants (Number)
MBEMBE and/or CRBEAny bleeding event
Dabigatran 150 mg1564200
Warfarin22102285

Number of Participants With Recurrent Symptomatic DVT

Symptomatic DVT which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg2528
Warfarin1717

Number of Participants With Recurrent Symptomatic Fatal and Non-fatal PE

Symptomatic fatal and non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg810
Warfarin1315

Number of Participants With Recurrent Symptomatic Non-fatal PE

Symptomatic non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg79
Warfarin1315

Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE

All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg3034
Warfarin2830

Number of Participants With Recurrent Symptomatic VTE and All Deaths

VTE or any death which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg5157
Warfarin4851

Laboratory Analyses

Frequency of patients with possible clinically significant abnormalities. (NCT00291330)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug)

,
Interventionparticipants (Number)
AST increaseAST decreaseALT increaseALT decreaseBilirubin increaseBilirubin decrease
Dabigatran 150 mg21026070
Warfarin220380130

Number of Participants Who Died (Any Cause)

Any deaths which occured from randomisation to end of post treatment period. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg2125
Warfarin2125

Number of Participants Who Died Due to VTE

"VTE - related deaths which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg11
Warfarin33

Number of Participants With Acute Coronary Syndrome (ACS)

"Any ACS occurring during the conduct of the study (centrally adjudicated as definite).~Counts of patients having a centrally adjudicated definite ACS during intake of active study drug, after stopping active study drug and before or without intake of active study drug, according to treatment group.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: From first intake of study drug to end of study conduct

,
Interventionparticipants (Number)
During intake of active study drugAfter stopping active study drugBefore/without intake of active study drug
Dabigatran 150 mg542
Warfarin320

Number of Participants With Bleeding Events

"Major bleeding events (MBE) were defined as~Fatal bleeding~Symptomatic bleeding in a critical area or organ~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells~Clinically-relevant bleeding events (CRBE) was defined as~spontaneous skin hematoma >=25 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding (more than spotting on toilet paper)~gingival bleeding >5 min~leading to hospitalisation and / or requiring surgical treatment~leading to a transfusion of <2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00291330)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug)

,
Interventionparticipants (Number)
Major bleeding eventsMBE and/or CRBEAny bleeding events
Dabigatran 150 mg2071207
Warfarin24111280

Number of Participants With Recurrent Symptomatic DVT

"Symptomatic DVT which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg1617
Warfarin1822

Number of Participants With Recurrent Symptomatic Non-fatal PE

"Symptomatic non-fatal PE which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg1316
Warfarin78

Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE

All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)

,
InterventionParticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg3034
Warfarin2732

Number of Participants With Recurrent Symptomatic VTE and All Deaths

"VTE or any death which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
InterventionParticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg4855
Warfarin4453

Gaps Days Between Prescription Refills for Dabigatran, Rivaroxaban, and Apixaban

The investigators will calculate the # of gap days between refills for dabigatran/rivaroxaban/apixaban for each3 and 6 months of the pilot intervention. This will be based on pharmacy refill data and calculated using the date dabigatran/rivaroxaban/apixaban was dispensed and the # of days supplied for that prescription. We will add the # of gap days for each 3 and 6 months of the pilot for each patient, and compare the total # of gaps days between intervention and usual care patients. The gap days between refills is a validated measure of adherence and identifies patients with sub-optimal adherence.A negative gap day value indicates that participants received the refill prior to completion of the previous prescription. (NCT01578044)
Timeframe: 3 and 6 months

,
Interventiondays (Number)
# of Patient gap days for 3-months of intervention# of Patient gap days for 6-months of intervention
Intervention Group4341
Usual Care Group51-5

Apixaban Plasma Concentration, Cmax

Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose

Interventionng/mL (Geometric Mean)
Apixaban 2.5 mg59.7
Apixaban 5 mg97.9

Apixaban Plasma Concentration, Cmin

Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose

Interventionng/mL (Geometric Mean)
Apixaban 2.5 mg28.2
Apixaban 5mg49.7

Area Under the Plasma Apixaban Concentration Curve From 0 to 12 Hours After Dose (AUCO-12)

Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0 to 12 hours after dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose

Interventionng*h/mL (Geometric Mean)
Apixaban 2.5 mg507
Apixaban 5mg868

Number of Participants Experiencing ISTH (International Society on Thrombosis and Haemostasis) Major or Clinically Relevant Non-major Bleeding

"Assess the safety of apixaban versus warfarin regarding ISTH major bleeding or clinically relevant non-major bleeding events in patients with NVAF (nonvalvular atrial fibrillation) and ESRD (end-stage renal disease) on hemodialysis.~Major bleeding event is defined as:Acute clinically overt bleeding (including access site related bleeding) accompanied by 1 or more of the following: Decrease in Hgb of 2g/dL or more with overt bleeding; Transfusion of 2 or more units of packed RBCs in the setting of an overt bleeding event; Bleeding within a critical site. Hemorrhagic stroke (primary or infarction with hemorrhagic conversion) were classified as major bleeds.~Non-major bleeding event is defined as: Acute or sub-acute clinically overt bleeding (including access site related bleeding) that does not meet criteria for major bleeding & results in Hospital admission for bleeding, physician guided medical or surgical treatment for bleeding, or change in antithrombotic therapy" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban21
Warfarin16

Number of Participants Experiencing Mortality

Evaluate mortality rates for those participants randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban21
Warfarin13

Number of Participants Experiencing Stroke

"Adjudcated stroke defined as a new, non-traumatic episode of focal or global neurological dysfunction of sudden onset caused by central nervous system (CNS) vascular injury as a result of hemorrhage or infarction and not due to a readily identifiable non-vascular cause (i.e. brain tumor). CNS includes brain, spinal cord and retina. The required duration of the deficit is ≥ 24 hours.~Events with neurologic deficit lasting for < 24 hours and an imaging modality showing evidence of an acute stroke will be counted as stroke as well.~A retinal ischemic event (embolism, infarction) will be considered a stroke" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban2
Warfarin2

Number of Participants Experiencing Stroke or Systemic Embolism

Number of participants experiencing adjudicated stroke or systemic embolism. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban2
Warfarin2

Number of Participants Experiencing Stroke, Systemic Embolism, Major Bleeding or All-cause Mortality

"Evaluate those experiencing stroke, systemic embolism, ISTH major bleeding, or all-cause mortality for those randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis~Definitions of stroke and systemic embolism are provided under the measurement description of the secondary outcomes for each individual event. Definition of major bleed is provided in outcome measurement description of the primary outcome measure." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban27
Warfarin29

Number of Participants Experiencing Systemic Embolism

"Adjudicated diagnosis of systemic arterial embolism (Non-pulmonary, non-cranial events) will require a positive clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which is supported by evidence of embolism/thrombosis from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.~Clinical presentation would include:~Abrupt development of pain, absent pulses, pallor, and/or paresis in an extremity (at least an entire digit) without previous severe claudication or findings of severe peripheral vascular disease.~Renal embolism will be diagnosed when sudden flank pain or a change in renal laboratory findings occurred.~Abdominal vascular/visceral embolism was considered definite if acute abdominal symptoms or referred symptoms developed along with a change in abdominal examination or appropriate laboratory values." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban0
Warfarin0

Persistence of Therapy

Evaluate days between time from initiation to discontinuation of randomized therapy. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionDays (Mean)
Apixaban304.4
Warfarin279.6

Cmin,1 of Unbound Sum (Free) Dabigatran

Cmin,1 (Minimum concentrations at any time point since the end of first vial of idarucizumab up to 4 hours after the completion of second vial) of unbound sum (free) dabigatran, provided that two vials given not more than 15 min apart in group A and B. (NCT02104947)
Timeframe: Since the end of first vial of idarucizumab up to 4 hours after the completion of second vial

Interventionng/mL (Geometric Mean)
Idarucizumab (Group A & B)1.12

Occurrence of Major/Life-threatening/Fatal Bleeding (for Group B Only) Intraoperatively

Occurrence of major/life-threatening/fatal bleeding (for group B only) intraoperatively and up to 24 hours post-surgery were classified according to major or life-threatening bleeding (ISTH [International Society for Thrombosis and Hemostasis] definition). 95% Confidence Interval (CI) is from Clopper-Pearson method. (NCT02104947)
Timeframe: within 24 hours of surgery

Interventionpercentage of participants (Number)
Idarucizumab (Group B)3.0

Time to Cessation of Bleeding (for Group A Only)

Time to cessation of bleeding (for Group A only) since first infusion up to 24 hours after the completion of second infusion; bleeding status was to be categorized before and at several time points after treatment. (NCT02104947)
Timeframe: from the first infusion up to 24 hours after the last infusion on Day 1

Interventionhours (Median)
ICH (Group A)10.73
Non-ICH (Group A)2.49

Duration of Reversal

Duration of reversal, defined as the time period a patient remained completely reversed based on dTT or ECT, up to 24 hours or re-starting the treatment of dabigatran. (NCT02104947)
Timeframe: from the first infusion up to 24 hours after the last infusion on Day 1

,
Interventionhours (Mean)
ECT (# patients evaluable for reversal=276; 185)dTT (# patients evaluable for reversal=244; 152)
Idarucizumab (Group A)13.219.8
Idarucizumab (Group B)12.818.8

Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of dTT or ECT

"Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of diluted thrombin time (dTT) or ecarin clotting time (ECT), at any time point from the end of the first infusion up to 4 hours after the last infusion.~Reversal is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% ULN (evaluable patients).~Reversal is calculated as 100* (pre-dose value minus post dose value)/(pre-dose value minus 100% x ULN); if calculated reversal is > 100, it was set to 100." (NCT02104947)
Timeframe: from the end of the first infusion up to 4 hours after the last infusion on Day 1

,
Interventionpercentage (Median)
dTT (# patients evaluable for reversal=244; 152)ECT (# patients evaluable for reversal=276; 185)
Idarucizumab (Group A)100.0100.0
Idarucizumab (Group B)100.0100.0

Reversal of Anticoagulation as Measured by Diluted Thrombin Time (dTT) or Ecarin Clotting Time (ECT) After the First Vial of Idarucizumab and Before the Start of Second Vial

"Reversal of anticoagulation as measured by diluted Thrombin Time (dTT) or Ecarin Clotting Time (ECT) after the first vial of idarucizumab and before the start of second vial.~Reversal is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% ULN (evaluable patients). Reversal is calculated as 100*(pre-dose value minus post dose value)/(pre-dose value minus 100% x ULN); if calculated reversal is > 100, it was set to 100." (NCT02104947)
Timeframe: after the first vial of idarucizumab and before the start of second vial on Day1

,
Interventionpercentage (Median)
dTT (# patients evaluable for reversal=240; 150)ECT (# patients evaluable for reversal=271; 182)
Idarucizumab (Group A)100.0100.0
Idarucizumab (Group B)100.0100.0

Reversal of aPTT and TT From Central Laboratory

"Reversal of anticoagulation as measured by Activated Partial Thromboplastin Time (aPTT) and Thrombin time (TT), at any time point since the end of first infusion up to 4 hours after the completion of the last infusion. Reversal is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% ULN (evaluable patients).~Reversal is calculated as 100* (pre-dose value minus post dose value)/(pre-dose value minus 100% x ULN); if calculated reversal is > 100, it was set to 100." (NCT02104947)
Timeframe: from the end of the first infusion up to 4 hours after the last infusion on Day 1

,
Interventionpercentage (Median)
aPTT (# patients evaluable for reversal=232; 141)TT (# patients evaluable for reversal=278; 188)
Idarucizumab (Group A)100.0100.0
Idarucizumab (Group B)100.0100.0

Number of Participants Who Died During Treatment Period

All cause death, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days

InterventionParticipants (Number)
Dabigatran 220mg0
Enoxaparin1

Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period

Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days

InterventionParticipants (Number)
Dabigatran 220mg18
Enoxaparin33

Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period

Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days

InterventionParticipants (Number)
Dabigatran 220mg17
Enoxaparin31

Number of Participants With Pulmonary Embolism During Treatment Period

Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days

InterventionParticipants (Number)
Dabigatran 220mg1
Enoxaparin2

Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period

Symptomatic Deep Vein Thrombosis, confirmed by venous duplex, ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days

InterventionParticipants (Number)
Dabigatran 220mg0
Enoxaparin4

Number of Participants With Total Deep Vein Thrombosis During Treatment Period

Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days

InterventionParticipants (Number)
Dabigatran 220mg60
Enoxaparin67

Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period

"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00657150)
Timeframe: 28-35 days

InterventionParticipants (Number)
Dabigatran 220mg61
Enoxaparin69

Volume of Blood Loss

Volume of blood loss for treated and operated patients during surgery. (NCT00657150)
Timeframe: Day 1

InterventionmL (Mean)
Dabigatran 220mg404.9
Enoxaparin411.0

Blood Transfusion

Number of treated and operated patients with required blood transfusion on day of surgery. (NCT00657150)
Timeframe: Day 1

,
Interventionparticipants (Number)
Transfusions requiredMissing
Dabigatran 220mg2464
Enoxaparin2377

Laboratory Analyses

Frequency of patients with possible clinically significant abnormalities. (NCT00657150)
Timeframe: First administration to end of study

,
Interventionparticipants (Number)
AST increase N=(964;962)AST decrease N=(964;962)ALT increase N=(966;962)ALT decrease N=(966;962)Bilirubin increase N=(966;962)Bilirubin decrease N=(966;962)
Dabigatran 220mg28034030
Enoxaparin44067010

Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period

"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00657150)
Timeframe: 28-35 days

,
InterventionParticipants (Number)
Major bleeding eventsMajor and clinically relevant bleeding eventsAny bleeding events
Dabigatran 220mg143798
Enoxaparin92983

Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period

Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00657150)
Timeframe: 3 months

,
InterventionParticipants (Number)
Total VTE and all-cause mortalityasymptomatic Deep Vein Thrombosissymptomatic Deep Vein ThrombosisPulmonary Embolismdeath
Dabigatran 220mg20110
Enoxaparin41021

Reviews

104 reviews available for beta-alanine and Bleeding

ArticleYear
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    The Cochrane database of systematic reviews, 2018, 06-19, Volume: 6

    Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabiga

2018
Managing new oral anticoagulants in the perioperative and intensive care unit setting.
    Anesthesiology, 2013, Volume: 118, Issue:6

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Critical Care; Dabigatran; Hemor

2013
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.
    Emergency medicine journal : EMJ, 2014, Volume: 31, Issue:2

    Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Disease Management

2014
Dabigatran: life-threatening bleeding.
    Prescrire international, 2013, Volume: 22, Issue:135

    Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Interactions;

2013
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Hospital practice (1995), 2013, Volume: 41, Issue:1

    Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; bet

2013
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
    Hospital practice (1995), 2013, Volume: 41, Issue:1

    Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombin

2013
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
    Journal of hepatology, 2013, Volume: 59, Issue:2

    Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Progression; Fibrinolytic

2013
Reversal of oral anticoagulation.
    Pharmacotherapy, 2013, Volume: 33, Issue:11

    Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabi

2013
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
    International journal of clinical practice, 2013, Volume: 67, Issue:7

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini

2013
Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.
    Journal of medical economics, 2013, Volume: 16, Issue:7

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran

2013
[Direct oral thrombin inhibitor, "dabigatran"].
    Nihon rinsho. Japanese journal of clinical medicine, 2013, Volume: 71, Issue:1

    Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2013
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
    Contributions to nephrology, 2013, Volume: 179

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; C

2013
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2013, Volume: 102, Issue:6

    Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatr

2013
Managing bleeding in anticoagulated patients in the emergency care setting.
    The Journal of emergency medicine, 2013, Volume: 45, Issue:3

    Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; He

2013
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2013, Volume: 16, Issue:4

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Ben

2013
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
    Heart failure reviews, 2014, Volume: 19, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug

2014
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
    Critical care (London, England), 2013, Jun-17, Volume: 17, Issue:3

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management;

2013
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Cleveland Clinic journal of medicine, 2013, Volume: 80, Issue:7

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring;

2013
The perioperative management of new direct oral anticoagulants: a question without answers.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:3

    Topics: Administration, Oral; Aged; Anesthesiology; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl

2013
Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire international, 2013, Volume: 22, Issue:139

    Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug O

2013
Dabigatran and kidney disease: a bad combination.
    Clinical journal of the American Society of Nephrology : CJASN, 2013, Volume: 8, Issue:9

    Topics: Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Coagulation

2013
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Clinical therapeutics, 2013, Volume: 35, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpr

2013
Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.
    British journal of haematology, 2013, Volume: 163, Issue:2

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug

2013
Bleeding and antidotes in new oral anticoagulants.
    Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabig

2013
[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].
    Annales francaises d'anesthesie et de reanimation, 2013, Volume: 32, Issue:10

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Emergency Medical Services; F

2013
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
    BMJ (Clinical research ed.), 2013, Aug-30, Volume: 347

    Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines;

2013
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
    Annals of internal medicine, 2013, Aug-20, Volume: 159, Issue:4

    Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
    Hematology. American Society of Hematology. Education Program, 2013, Volume: 2013

    Topics: Antibodies; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials

2013
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:3

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage;

2014
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
    Drug and therapeutics bulletin, 2014, Volume: 52, Issue:1

    Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Fact

2014
Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran.
    The American journal of cardiology, 2014, Mar-15, Volume: 113, Issue:6

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Global Health; Hemorrh

2014
New antithrombotics for secondary prevention of acute coronary syndrome.
    Clinical cardiology, 2014, Volume: 37, Issue:3

    Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cor

2014
New oral anticoagulant agents - general features and outcomes in subsets of patients.
    Thrombosis and haemostasis, 2014, Apr-01, Volume: 111, Issue:4

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as To

2014
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
    European heart journal, 2014, Jul-21, Volume: 35, Issue:28

    Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, P

2014
Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants.
    The American journal of emergency medicine, 2014, Volume: 32, Issue:4

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emerg

2014
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
    Circulation. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzi

2014
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2014, Volume: 29, Issue:3

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interaction

2014
Risk of major bleeding and the standard doses of dabigatran.
    European journal of internal medicine, 2014, Volume: 25, Issue:6

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Ra

2014
The newer direct oral anticoagulants: a practical guide.
    Clinical medicine (London, England), 2014, Volume: 14, Issue:2

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2014
New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
    Acta anaesthesiologica Scandinavica, 2014, Volume: 58, Issue:6

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring;

2014
Anticoagulation in atrial fibrillation.
    BMJ (Clinical research ed.), 2014, Apr-14, Volume: 348

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M

2014
Anticoagulation in atrial fibrillation.
    BMJ (Clinical research ed.), 2014, Apr-14, Volume: 348

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M

2014
Anticoagulation in atrial fibrillation.
    BMJ (Clinical research ed.), 2014, Apr-14, Volume: 348

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M

2014
Anticoagulation in atrial fibrillation.
    BMJ (Clinical research ed.), 2014, Apr-14, Volume: 348

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M

2014
Anticoagulation: a GP primer on the new oral anticoagulants.
    Australian family physician, 2014, Volume: 43, Issue:5

    Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atri

2014
Newer clinically available antithrombotics and their antidotes.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 40, Issue:3

    Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Elec

2014
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Thrombosis research, 2014, Volume: 134, Issue:4

    Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage;

2014
Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    International angiology : a journal of the International Union of Angiology, 2014, Volume: 33, Issue:4

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigat

2014
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:8

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans;

2014
Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.
    BioMed research international, 2014, Volume: 2014

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials as Topic; D

2014
Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
    Clinics in laboratory medicine, 2014, Volume: 34, Issue:3

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Evi

2014
Management of hemorrhage with the target-specific oral anticoagulants.
    Hospital practice (1995), 2014, Volume: 42, Issue:3

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Transfusion; Charcoal; Dab

2014
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
    Nature reviews. Cardiology, 2014, Volume: 11, Issue:12

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors;

2014
[Bleeding complications under oral anticoagulation].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:49

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigat

2014
Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
    International journal of cardiology, 2015, Jan-20, Volume: 179

    Topics: Administration, Oral; Antithrombins; Azepines; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran;

2015
Strategies for urgent reversal of target-specific oral anticoagulants.
    Hospital practice (1995), 2014, Volume: 42, Issue:5

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Charc

2014
Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
    British journal of biomedical science, 2014, Volume: 71, Issue:4

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relati

2014
Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban.
    Current opinion in critical care, 2015, Volume: 21, Issue:2

    Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor Xa I

2015
[Anticoagulant therapy in secondary prevention of coronary events].
    Vnitrni lekarstvi, 2014, Volume: 60, Issue:12

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine

2014
Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.
    Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:4

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, R

2015
Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.
    Archives of pathology & laboratory medicine, 2015, Volume: 139, Issue:5

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation

2015
[Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure].
    Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140, Issue:16

    Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine;

2015
Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Cardiovascular therapeutics, 2010, Volume: 28, Issue:5

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; He

2010
Managing bleeding complications in patients treated with the old and the new anticoagulants.
    Current pharmaceutical design, 2010, Volume: 16, Issue:31

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor VIIa; Fondaparinux; Hemorrhage; Hep

2010
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
    Journal of clinical pharmacy and therapeutics, 2011, Volume: 36, Issue:1

    Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhib

2011
New anticoagulants: pharmacology and clinical studies.
    Wiener medizinische Wochenschrift (1946), 2011, Volume: 161, Issue:3-4

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation

2011
Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
    International angiology : a journal of the International Union of Angiology, 2011, Volume: 30, Issue:3

    Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Evidence-Based

2011
New anticoagulants: how to deal with treatment failure and bleeding complications.
    British journal of clinical pharmacology, 2011, Volume: 72, Issue:4

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxab

2011
Anticoagulating obese patients in the modern era.
    British journal of haematology, 2011, Volume: 155, Issue:2

    Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dab

2011
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.
    Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2011, Volume: 7, Issue:4

    Topics: Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Human

2011
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
    Thrombosis and haemostasis, 2011, Volume: 106, Issue:5

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2011
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
    Current neurology and neuroscience reports, 2012, Volume: 12, Issue:1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as

2012
Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
    Journal of cardiothoracic and vascular anesthesia, 2011, Volume: 25, Issue:6

    Topics: Anesthesia, Conduction; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry

2011
[Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
    Kardiologiia, 2011, Volume: 51, Issue:11

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu

2011
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
    Cardiology journal, 2012, Volume: 19, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat

2012
A new generation of oral direct anticoagulants.
    Arteriosclerosis, thrombosis, and vascular biology, 2012, Volume: 32, Issue:3

    Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimi

2012
The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2012, Volume: 18, Issue:6

    Topics: Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta

2012
Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
    Prescrire international, 2012, Volume: 21, Issue:124

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; I

2012
[New antithrombotic drugs].
    Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:7

    Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans

2012
[Dabigatran and emergency operation on a peritonitis patient].
    Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:7

    Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dialysis; Emergency Treatment; Factor VIIa;

2012
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:1

    Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogr

2012
[Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].
    MMW Fortschritte der Medizin, 2012, Mar-22, Volume: 154, Issue:5

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eviden

2012
New oral anticoagulants: will they replace warfarin?
    Oral surgery, oral medicine, oral pathology and oral radiology, 2012, Volume: 113, Issue:5

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Hypersensitivit

2012
[Prevention of cardioembolic stroke].
    Neurologia (Barcelona, Spain), 2012, Volume: 27 Suppl 1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Doubl

2012
[Clinical management of the new anticoagulants].
    Neurologia (Barcelona, Spain), 2012, Volume: 27 Suppl 1

    Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Clinic

2012
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
    Coronary artery disease, 2012, Volume: 23, Issue:6

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazole

2012
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:3

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tri

2012
Complications of anticoagulation.
    Disease-a-month : DM, 2012, Volume: 58, Issue:8

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Contamination;

2012
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:10

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2012
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
    Canadian family physician Medecin de famille canadien, 2012, Volume: 58, Issue:8

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Tech

2012
Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:4

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:4

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Pr

2012
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:5

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, R

2012
What did we learn from new oral anticoagulant treatment?
    Thrombosis research, 2012, Volume: 130 Suppl 1

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; B

2012
Antithrombotic treatment of atrial fibrillation: new insights.
    Thrombosis research, 2012, Volume: 130 Suppl 1

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
Laboratory tests and the new oral anticoagulants.
    Thrombosis research, 2012, Volume: 130 Suppl 1

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagula

2012
[Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation].
    Kardiologiia, 2012, Volume: 52, Issue:9

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coa

2012
Management of dabigatran-induced anticoagulation in trauma and acute care surgery patients.
    The journal of trauma and acute care surgery, 2012, Volume: 73, Issue:5

    Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Woun

2012
[Clinical pharmacological aspects of new oral anticoagulants].
    Therapeutische Umschau. Revue therapeutique, 2012, Volume: 69, Issue:11

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP3A; Cytochro

2012
New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:18

    Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
Acute management of bleeding in patients on novel oral anticoagulants.
    European heart journal, 2013, Volume: 34, Issue:7

    Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alani

2013
Perioperative management of patients on chronic antithrombotic therapy.
    Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012

    Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic A

2012
[New anticoagulants--are we prepared?].
    Przeglad lekarski, 2012, Volume: 69, Issue:8

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans;

2012
[Pharmacovigilance update].
    Revue medicale suisse, 2013, Jan-09, Volume: 9, Issue:368

    Topics: Adrenergic Uptake Inhibitors; Age Factors; Aged; Amides; Antihypertensive Agents; Atomoxetine Hydroc

2013
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
    The Journal of emergency medicine, 2013, Volume: 45, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emerge

2013
Thrombin inhibitors: surgical considerations and pharmacology.
    ANZ journal of surgery, 2013, Volume: 83, Issue:4

    Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatr

2013

Trials

21 trials available for beta-alanine and Bleeding

ArticleYear
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
    The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow

2013
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
    Journal of the American College of Cardiology, 2013, Sep-03, Volume: 62, Issue:10

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2013
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Circulation, 2013, Jul-16, Volume: 128, Issue:3

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2013
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Circulation, 2013, Jul-16, Volume: 128, Issue:3

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2013
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Circulation, 2013, Jul-16, Volume: 128, Issue:3

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2013
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Circulation, 2013, Jul-16, Volume: 128, Issue:3

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2013
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Clinical therapeutics, 2013, Volume: 35, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpr

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
    Circulation, 2014, Feb-18, Volume: 129, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine;

2014
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
    Circulation, 2014, Feb-18, Volume: 129, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine;

2014
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
    Circulation, 2014, Feb-18, Volume: 129, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine;

2014
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
    Circulation, 2014, Feb-18, Volume: 129, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine;

2014
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
    Circulation, 2014, Feb-18, Volume: 129, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine;

2014
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
    Circulation, 2014, Feb-18, Volume: 129, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine;

2014
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
    Circulation, 2014, Feb-18, Volume: 129, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine;

2014
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
    Circulation, 2014, Feb-18, Volume: 129, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine;

2014
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
    Circulation, 2014, Feb-18, Volume: 129, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine;

2014
Warfarin or dabigatran for treatment of atrial fibrillation.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:7

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Europe; Hemorrh

2014
Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2014, Volume: 20, Issue:7

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, F

2014
[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2014, Volume: 37, Issue:221

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibi

2014
Idarucizumab for Dabigatran Reversal.
    The New England journal of medicine, 2015, Aug-06, Volume: 373, Issue:6

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Benzimidazoles; beta-Ala

2015
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:6

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet

2010
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
    Circulation, 2011, Jan-18, Volume: 123, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Echocardiography, Tra

2011
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
    Thrombosis and haemostasis, 2011, Volume: 105, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimida

2011
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Ala

2011
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
    European heart journal, 2011, Volume: 32, Issue:22

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-

2011
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Circulation, 2011, May-31, Volume: 123, Issue:21

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alan

2011
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
    Annals of internal medicine, 2011, Nov-15, Volume: 155, Issue:10

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2011
Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:3

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Respons

2012
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Thrombosis research, 2012, Volume: 130, Issue:2

    Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazol

2012
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Circulation, 2012, Jul-17, Volume: 126, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I

2012
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Circulation, 2012, Jul-17, Volume: 126, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I

2012
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Circulation, 2012, Jul-17, Volume: 126, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I

2012
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Circulation, 2012, Jul-17, Volume: 126, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I

2012

Other Studies

176 other studies available for beta-alanine and Bleeding

ArticleYear
Case Report: Intracorneal Hemorrhages Seen with Scleral Contact Lens Wear and Netarsudil Therapy.
    Optometry and vision science : official publication of the American Academy of Optometry, 2022, 04-01, Volume: 99, Issue:4

    Topics: Aged; Benzoates; beta-Alanine; Contact Lenses; Glaucoma, Open-Angle; Hemorrhage; Humans; Male; Scler

2022
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
    Hospital practice (1995), 2013, Volume: 41, Issue:1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as

2013
Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity.
    Critical care medicine, 2013, Volume: 41, Issue:5

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; C

2013
Dabigatran and postmarketing reports of bleeding.
    The New England journal of medicine, 2013, Apr-04, Volume: 368, Issue:14

    Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Gastrointestinal Hemorrhage

2013
Letter by David et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) Randomized Trial".
    Circulation, 2013, Mar-19, Volume: 127, Issue:11

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Thromboembolism; War

2013
Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".
    Circulation, 2013, Mar-19, Volume: 127, Issue:11

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Thromboembolism; War

2013
Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
    Annals of emergency medicine, 2013, Volume: 61, Issue:4

    Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzi

2013
Venous thromboembolism: prophylactic and therapeutic practice guideline.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2013, Feb-15, Volume: 103, Issue:4 Pt 2

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chemoprevention; Dabigatran; Disease Management; Dose-

2013
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
    Kardiologiia, 2013, Volume: 53, Issue:3

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzimidazoles; beta-Alanine; C

2013
The use, misuse and abuse of dabigatran.
    The Medical journal of Australia, 2013, Apr-15, Volume: 198, Issue:7

    Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardio

2013
Is there really misuse and abuse of dabigatran?
    The Medical journal of Australia, 2013, Apr-15, Volume: 198, Issue:7

    Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Myocard

2013
Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013, Volume: 62, Issue:3

    Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Lung

2013
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
    Clinical pharmacology and therapeutics, 2013, Volume: 94, Issue:2

    Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular

2013
New approaches to reversing oral anticoagulant therapy. Introduction.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, May-15, Volume: 70, Issue:10 Suppl 1

    Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-A

2013
Pharmacologic interventions for reversing the effects of oral anticoagulants.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, May-15, Volume: 70, Issue:10 Suppl 1

    Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-A

2013
Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.
    Circulation, 2013, Mar-19, Volume: 127, Issue:11

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Thromboembolism; War

2013
Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
    Journal of cardiology, 2013, Volume: 62, Issue:2

    Topics: Age Factors; Aged; Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fi

2013
Dabigatran and bleeding: still an emergent situation?
    The American journal of the medical sciences, 2013, Volume: 346, Issue:3

    Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor VIIa; Factor VI

2013
Uncontrollable haemorrhage following dabigatran prophylaxis.
    BMJ case reports, 2013, Jun-10, Volume: 2013

    Topics: Abdomen; Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency

2013
The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dr

2013
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine;

2013
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabet

2013
Dabigatran and mechanical valves: less effective and more risky than warfarin.
    Prescrire international, 2013, Volume: 22, Issue:138

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Prosthesis; Heart Valve Prosth

2013
Adherence to anticoagulant treatment with dabigatran in a real-world setting.
    Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; b

2013
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
    Circulation, 2013, Aug-13, Volume: 128, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine;

2013
[New anticoagulants, new emergencies?].
    Praxis, 2013, Jul-24, Volume: 102, Issue:15

    Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Female; Hemorr

2013
Dabigatran monitoring made simple?
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:3

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation

2013
Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin.
    Journal of cardiovascular electrophysiology, 2013, Volume: 24, Issue:10

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cardiac Pacing, Artificial; D

2013
Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.
    Thrombosis research, 2013, Volume: 132, Issue:2

    Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Data Collection; Female; He

2013
Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Circulation. Cardiovascular quality and outcomes, 2013, Sep-01, Volume: 6, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
The promise of pharmacoepidemiology in helping clinicians assess drug risk.
    Circulation, 2013, Aug-13, Volume: 128, Issue:7

    Topics: Administration, Oral; Advertising; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine

2013
Reversal of a dabigatran overdose: what are possible options?
    The American journal of the medical sciences, 2013, Volume: 346, Issue:3

    Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor VIIa; Hemorrhag

2013
Dabigatran - neurosurgical anathema?
    The Medical journal of Australia, 2013, Aug-19, Volume: 199, Issue:4

    Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male; Risk Assess

2013
Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2014, Volume: 29, Issue:12

    Topics: Acute Kidney Injury; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatra

2014
The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
    Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran

2013
Fatal bleeding associated with dabigatran.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, Oct-01, Volume: 70, Issue:19

    Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; Female; Hemorrhage; Humans

2013
Anticoagulation without monitoring.
    American journal of clinical pathology, 2013, Volume: 140, Issue:5

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Heparin; Huma

2013
Intravenous lipid emulsion does not reverse dabigatran-induced anticoagulation in a rat model.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2013, Volume: 20, Issue:10

    Topics: Administration, Oral; Animals; Antithrombins; Benzimidazoles; beta-Alanine; Bleeding Time; Blood Coa

2013
Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department.
    Haematologica, 2013, Volume: 98, Issue:11

    Topics: Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors;

2013
Renal risk stratification with the new oral anticoagulants (July 2013).
    Cleveland Clinic journal of medicine, 2013, Volume: 80, Issue:11

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones;

2013
A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.
    Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Da

2014
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
    Journal of the American Heart Association, 2013, Nov-25, Volume: 2, Issue:6

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Ben

2013
[Prevention and treatment of major bleeding during anticoagulation].
    Rinsho shinkeigaku = Clinical neurology, 2013, Volume: 53, Issue:11

    Topics: Administration, Oral; Alcohol Drinking; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemor

2013
Evaluation of dabigatran exposures reported to poison control centers.
    The Annals of pharmacotherapy, 2014, Volume: 48, Issue:3

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Benzimidazoles; beta-Alanine;

2014
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
    Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; D

2014
In reply.
    Cleveland Clinic journal of medicine, 2013, Volume: 80, Issue:11

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones;

2013
Direct oral anticoagulants for acute venous thromboembolism: closing the circle?
    Circulation, 2014, Feb-18, Volume: 129, Issue:7

    Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans;

2014
[Experience with rivaroxaban and dabigatran].
    Hamostaseologie, 2013, Volume: 33 Suppl 1

    Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy, Combination;

2013
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
    Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation

2014
[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery].
    Annales francaises d'anesthesie et de reanimation, 2014, Volume: 33, Issue:1

    Topics: Acute Kidney Injury; Aged, 80 and over; Alzheimer Disease; Antithrombins; Atrial Fibrillation; Benzi

2014
Activated prothrombin complex concentrate for dabigatran-associated bleeding.
    British journal of haematology, 2014, Volume: 164, Issue:2

    Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Brain; Dabigatran; Female; Hematoma,

2014
How I treat target-specific oral anticoagulant-associated bleeding.
    Blood, 2014, Feb-20, Volume: 123, Issue:8

    Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-A

2014
Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2014
Impaired renal function and bleeding in elderly treated with dabigatran.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2014, Volume: 25, Issue:6

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2014
Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
    The American journal of medicine, 2014, Volume: 127, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2014
[Extrapolation of physiopathological data to clinical practice: Example of dabigatran in off-label use].
    Presse medicale (Paris, France : 1983), 2014, Volume: 43, Issue:4 Pt 1

    Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Contraindications; Dabigatr

2014
Fatal dabigatran-associated bleeding.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2014, Mar-01, Volume: 71, Issue:5

    Topics: Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans

2014
Fatal dabigatran-associated bleeding.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2014, Mar-01, Volume: 71, Issue:5

    Topics: Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans

2014
Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2014, Volume: 34, Issue:5

    Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors;

2014
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:8

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cathe

2014
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini

2014
Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding.
    British journal of haematology, 2014, Volume: 166, Issue:1

    Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatra

2014
Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.
    Pharmacotherapy, 2014, Volume: 34, Issue:6

    Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Ben

2014
ACP Journal Club. Review: Dabigatran does not differ from vitamin K antagonists for mortality or major bleeding.
    Annals of internal medicine, 2014, Apr-15, Volume: 160, Issue:8

    Topics: Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Thromboembo

2014
Perioperative management of patients on new oral anticoagulants.
    The British journal of surgery, 2014, Volume: 101, Issue:7

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological

2014
[Not Available].
    Praxis, 2014, May-07, Volume: 103, Issue:10

    Topics: Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Thromboembo

2014
Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapy.
    Evidence-based medicine, 2014, Volume: 19, Issue:5

    Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venou

2014
Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
    Seminars in hematology, 2014, Volume: 51, Issue:2

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; D

2014
Direct oral anticoagulants in atrial fibrillation.
    Seminars in hematology, 2014, Volume: 51, Issue:2

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2014
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
    American heart journal, 2014, Volume: 167, Issue:6

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St

2014
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
    American heart journal, 2014, Volume: 167, Issue:6

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St

2014
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
    American heart journal, 2014, Volume: 167, Issue:6

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St

2014
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
    American heart journal, 2014, Volume: 167, Issue:6

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St

2014
Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
    Scandinavian journal of clinical and laboratory investigation, 2014, Volume: 74, Issue:7

    Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Dabigatra

2014
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
    Internal medicine journal, 2014, Volume: 44, Issue:6

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu

2014
Dabigatran: how the drug company withheld important analyses.
    BMJ (Clinical research ed.), 2014, Jul-23, Volume: 349

    Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Drug Appr

2014
The trouble with dabigatran.
    BMJ (Clinical research ed.), 2014, Jul-23, Volume: 349

    Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Drug Appr

2014
Concerns over data in key dabigatran trial.
    BMJ (Clinical research ed.), 2014, Jul-23, Volume: 349

    Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Dose-Resp

2014
Dabigatran, bleeding, and the regulators.
    BMJ (Clinical research ed.), 2014, Jul-23, Volume: 349

    Topics: Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Dose-Response Rel

2014
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
    Journal of medical economics, 2014, Volume: 17, Issue:11

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fees, Pharmaceutical; Health Expenditures;

2014
Continuation of dabigatran therapy in "real-world" practice in Hong Kong.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2014
Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.
    The American journal of medicine, 2014, Volume: 127, Issue:12

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2014
Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants.
    Heart, lung & circulation, 2015, Volume: 24, Issue:1

    Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies

2015
Dabigatran in secondary stroke prevention: clinical experience with 106 patients.
    BioMed research international, 2014, Volume: 2014

    Topics: Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Female; Hemorrhag

2014
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
    Journal of medical economics, 2014, Volume: 17, Issue:11

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health

2014
Dabigatran: patient management in specific clinical settings.
    Wiener klinische Wochenschrift, 2014, Volume: 126, Issue:17-18

    Topics: Antithrombins; Arthroplasty, Replacement; Austria; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrh

2014
[New oral anticoagulants are as safe in elderly patients as conventional drugs].
    Praxis, 2014, Aug-20, Volume: 103, Issue:17

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; H

2014
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
    Kardiologiia, 2014, Volume: 54, Issue:7

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu

2014
Letter by Hifumi et al regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
    Circulation, 2014, Sep-02, Volume: 130, Issue:10

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venous Thromboe

2014
Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
    Circulation, 2014, Sep-02, Volume: 130, Issue:10

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venous Thromboe

2014
[Eligibility for dabigatran therapy: the real-life experience of a Tuscany general hospital].
    Recenti progressi in medicina, 2014, Volume: 105, Issue:9

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2014
Additional events in the RE-LY trial.
    The New England journal of medicine, 2014, Oct-09, Volume: 371, Issue:15

    Topics: Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic;

2014
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Circulation, 2015, Jan-13, Volume: 131, Issue:2

    Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles

2015
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Circulation, 2015, Jan-13, Volume: 131, Issue:2

    Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles

2015
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Circulation, 2015, Jan-13, Volume: 131, Issue:2

    Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles

2015
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Circulation, 2015, Jan-13, Volume: 131, Issue:2

    Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles

2015
The importance of postapproval data for dabigatran.
    JAMA internal medicine, 2015, Volume: 175, Issue:1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female

2015
Risk of bleeding with dabigatran in atrial fibrillation.
    JAMA internal medicine, 2015, Volume: 175, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz

2015
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 41, Issue:3

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbid

2014
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
    Canadian family physician Medecin de famille canadien, 2014, Volume: 60, Issue:11

    Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alani

2014
Atrial fibrillation: Risk of bleeding with dabigatran versus warfarin particularly high in CKD.
    Nature reviews. Nephrology, 2015, Volume: 11, Issue:1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran.
    British journal of haematology, 2015, Volume: 169, Issue:4

    Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male

2015
CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
    Thrombosis research, 2015, Volume: 135, Issue:1

    Topics: Adolescent; Adult; Aged; Algorithms; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazo

2015
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
    Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2014, Volume: 20, Issue:4

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coa

2014
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
    American heart journal, 2015, Volume: 169, Issue:1

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors;

2015
Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate.
    Anesthesiology, 2015, Volume: 122, Issue:2

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Factor VIIa; He

2015
Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.
    Hospital practice (1995), 2014, Volume: 42, Issue:4

    Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemor

2014
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    The Annals of pharmacotherapy, 2015, Volume: 49, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cathe

2015
[Advantages and disadvantages of warfarin and pradaxa therapy for venous thromboembolism].
    Vestnik khirurgii imeni I. I. Grekova, 2014, Volume: 173, Issue:4

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Dose-Response Relations

2014
[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room].
    Journal des maladies vasculaires, 2015, Volume: 40, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr

2015
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
    Circulation, 2015, Mar-17, Volume: 131, Issue:11

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr

2015
[Extended options of anticoagulant treatment in thromboembolism].
    Vnitrni lekarstvi, 2014, Volume: 60, Issue:11

    Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Czech Republic; Dabigatran;

2014
Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants.
    Nature reviews. Gastroenterology & hepatology, 2015, Volume: 12, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
[Dabigatran and risk of bleeding].
    Praxis, 2015, Jan-28, Volume: 104, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran.
    Clinical toxicology (Philadelphia, Pa.), 2015, Volume: 53, Issue:3

    Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagu

2015
What is the role of hemodialysis for dabigatran-associated major bleeding?
    Hematology. American Society of Hematology. Education Program, 2014, Dec-05, Volume: 2014, Issue:1

    Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male; Observational Studies as T

2014
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
    The American journal of cardiology, 2015, Mar-01, Volume: 115, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada;

2015
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
    MMW Fortschritte der Medizin, 2015, Jan-19, Volume: 157, Issue:1

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Drug Substitution; Half-L

2015
[Triple anticoagulant therapy - now what can I give for pain?].
    MMW Fortschritte der Medizin, 2015, Feb-19, Volume: 157, Issue:3

    Topics: Aged; Analgesics; Anticoagulants; Aspirin; Back Pain; Benzimidazoles; beta-Alanine; Clopidogrel; Con

2015
[Antidote to dabigatran].
    MMW Fortschritte der Medizin, 2015, Feb-19, Volume: 157, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Ris

2015
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
    Circulation, 2015, Apr-21, Volume: 131, Issue:16

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindic

2015
Perioperative Management of Dabigatran: A Prospective Cohort Study.
    Circulation, 2015, Jul-21, Volume: 132, Issue:3

    Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Di

2015
Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:10

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatr

2015
Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2015, Volume: 41, Issue:7

    Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Su

2015
Targeted Anti-Anticoagulants.
    The New England journal of medicine, 2015, Aug-06, Volume: 373, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Benzimidazoles; beta-Alanine; Female; Hemorrhage;

2015
One-Year Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation: Placing Real-World Results Into Perspective.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
Bleeding in Patients of African Ancestry Using Dabigatran: A Potential Effect of Creatine Kinase.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
The Role of Selection in the Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
A Methodological Appraisal of Recent Real-World Data Publications on Dabigatran.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
Dosage of Dabigatran as a Risk Factor for Bleeding in Atrial Fibrillation.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
Patient Characteristics and Risk of Bleeding With Dabigatran in Atrial Fibrillation.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug.
    Prescrire international, 2015, Volume: 24, Issue:161

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagula

2015
Letter by Lavine Regarding Article, "Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation".
    Circulation, 2015, Oct-06, Volume: 132, Issue:14

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Medicare; War

2015
Bleeding risk higher with rivaroxaban than dabigatran for stroke prevention, head-to-head trial shows.
    BMJ (Clinical research ed.), 2016, 10-03, Volume: 355

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2016
Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2017, Volume: 43, Issue:4

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgica

2017
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Annals of internal medicine, 2011, Jan-04, Volume: 154, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Ben

2011
Warfarin or not.
    The journal of the Royal College of Physicians of Edinburgh, 2010, Volume: 40, Issue:4

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Pulmonary Embolism; Ve

2010
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emboli

2011
Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran.
    Thrombosis and haemostasis, 2011, Volume: 106, Issue:1

    Topics: Aged; Antithrombins; Aphasia; Benzimidazoles; beta-Alanine; Carotid Artery Diseases; Dabigatran; Fem

2011
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
    Circulation, 2011, Jun-07, Volume: 123, Issue:22

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefi

2011
Ask the doctor. For several years, I have been taking warfarin because of atrial fibrillation. I recently suffered several nosebleeds, which took two days to control. The trauma of those episodes makes me want to swear off warfarin, but I am not sure what
    Harvard health letter, 2011, Volume: 36, Issue:7

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Health Knowledge

2011
Dabigatran in patients with nonvalvular atrial fibrillation.
    Journal of the American College of Cardiology, 2011, Jul-26, Volume: 58, Issue:5

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Dose-Resp

2011
[New anticoagulants: "efficacy and safety" or "efficacy or safety"].
    Journal des maladies vasculaires, 2011, Volume: 36, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans

2011
Dabigatran for stroke prevention in all patients with atrial fibrillation?
    Pharmacotherapy, 2011, Volume: 31, Issue:8

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr

2011
The use of dabigatran immediately after atrial fibrillation ablation.
    Journal of cardiovascular electrophysiology, 2012, Volume: 23, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2012
Lack of an antagonist to reverse the action of dabigatran.
    QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:2

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Hemorrhage; Hum

2012
Learning the respective roles of warfarin and dabigatran to prevent stroke in patients with nonvalvular atrial fibrillation.
    Annals of internal medicine, 2011, Nov-15, Volume: 155, Issue:10

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Fema

2011
Acutely injured patients on dabigatran.
    The New England journal of medicine, 2011, Nov-24, Volume: 365, Issue:21

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Thrombelastography; Wh

2011
Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation.
    The American journal of emergency medicine, 2012, Volume: 30, Issue:9

    Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Fe

2012
Letter by Govindarajan and Salgado regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male;

2012
Letter by Reynolds et al regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) tri
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male;

2012
Letter by Reiffel regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male;

2012
Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
    Journal of the American College of Cardiology, 2012, Mar-27, Volume: 59, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatr

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Dabigatran (Pradaxa).
    AJNR. American journal of neuroradiology, 2012, Volume: 33, Issue:3

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrha

2012
More on acutely injured patients receiving dabigatran.
    The New England journal of medicine, 2012, 03-01, Volume: 366, Issue:9

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Wounds and Injuries

2012
Bleeding risk with dabigatran in the frail elderly.
    The New England journal of medicine, 2012, Mar-01, Volume: 366, Issue:9

    Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Frail Elderly; Hem

2012
Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
    Age and ageing, 2012, Volume: 41, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles;

2012
Clinical challenges in a patient with dabigatran-induced fatal hemorrhage.
    The American journal of geriatric pharmacotherapy, 2012, Volume: 10, Issue:2

    Topics: Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; Female; Hemorrhage; H

2012
Avoiding adverse events with dabigatran by careful selection of eligible patients.
    The Medical journal of Australia, 2012, Apr-16, Volume: 196, Issue:7

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contr

2012
Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model.
    Journal of investigative surgery : the official journal of the Academy of Surgical Research, 2012, Volume: 25, Issue:3

    Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation, Preclinical; Fem

2012
Anticoagulation, novel agents, and procedures: can we pardon the interruption?
    Circulation, 2012, Jul-17, Volume: 126, Issue:3

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Thromboe

2012
Dabigatran: uncharted waters and potential harms.
    Annals of internal medicine, 2012, Jul-03, Volume: 157, Issue:1

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemor

2012
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Circulation. Cardiovascular quality and outcomes, 2012, Jul-01, Volume: 5, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini

2012
Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation.
    Journal of evaluation in clinical practice, 2013, Volume: 19, Issue:5

    Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eligibility De

2013
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
    Kardiologiia, 2012, Volume: 52, Issue:7

    Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazo

2012
The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis.
    Journal of thrombosis and thrombolysis, 2013, Volume: 35, Issue:1

    Topics: Aged, 80 and over; Anemia; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigat

2013
A comparison of bleeding complications post-ablation between warfarin and dabigatran.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:1

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Abl

2012
Hemorrhagic complications associated with dabigatran use.
    Clinical toxicology (Philadelphia, Pa.), 2012, Volume: 50, Issue:9

    Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage

2012
Diffuse alveolar hemorrhage associated with dabigatran.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:18

    Topics: Aged; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Dabigatran;

2012
A 77-year-old man with a prolonged activated partial thromboplastin time.
    Clinical chemistry, 2012, Volume: 58, Issue:10

    Topics: Aged; Anticoagulants; Autoantibodies; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Different

2012
Vascular insult accompanied by overexpressed heme oxygenase-1 as a pathophysiological mechanism in experimental neurolathyrism with hind-leg paraparesis.
    Biochemical and biophysical research communications, 2012, Nov-09, Volume: 428, Issue:1

    Topics: Animals; beta-Alanine; Blood Vessels; Disease Models, Animal; Heme Oxygenase-1; Hemorrhage; Human Um

2012
Periprocedural anticoagulant management.
    Hospital practice (1995), 2012, Volume: 40, Issue:3

    Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Restenosis; Dabigatran; Heart

2012
Faculty of Consulting Physicians of South Africa (FCPSA): saving brain with dabigatran.
    Cardiovascular journal of Africa, 2012, Volume: 23, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; I

2012
Editorial critique.
    The journal of trauma and acute care surgery, 2012, Volume: 73, Issue:5

    Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Woun

2012
Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:2

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2013
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
    Klinicheskaia meditsina, 2012, Volume: 90, Issue:10

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz

2012
Transitions of care in anticoagulation management for patients with atrial fibrillation.
    Hospital practice (1995), 2012, Volume: 40, Issue:4

    Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Ala

2012
Acute adrenal failure following anticoagulation with dabigatran after hip replacement and thrombolysis for massive pulmonary embolism.
    BMJ case reports, 2013, Jan-11, Volume: 2013

    Topics: Adrenal Gland Diseases; Adrenal Insufficiency; Aged; Antithrombins; Arthroplasty, Replacement, Hip;

2013
When dabigatran and trauma collide.
    The American surgeon, 2013, Volume: 79, Issue:1

    Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Dabigat

2013
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
    Revista espanola de salud publica, 2012, Volume: 86, Issue:6

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole

2012